SACHS ASSOCIATES ARE DELIGHTED TO WELCOME YOU TO THE:

12TH ANNUAL EUROPEAN LIFE SCIENCES CEO FORUM
FOR PARTNERING AND INVESTING IN BIOTECH & PHARMA INDUSTRY

25TH - 26TH FEBRUARY 2019
HILTON ZURICH AIRPORT HOTEL
SWITZERLAND

Back for its 12th Annual edition, this global bio-pharma industry forum addresses through its conference programme the main challenges for 2019 in investment, partnering and alliance management. Key players contribute their insights in panels which cover the macro picture as well as innovation in the different therapeutic sectors.

The forum also features keynote speeches by KOL and about 60 selected corporate presentations from established (public and private) and emerging biotechs seeking to promote investment and partnering opportunities. We expect over 350 delegates to attend the event. The forum will provide a number of networking opportunities via our online One-2-One meeting system which allows you to pre-book meetings with all the attendees at the dedicated meeting facilities. We anticipate more than 1500 face-to-face meetings to take place throughout 2 days.

This year, following our conference, in the afternoon of the 26th we will also host the 1st Go for Israel Life Sciences Conference. We will bring together leading global investors and Israel’s best opportunities from the Life Sciences industry, addressing current issues related to raising capital and establishing strategic alliances in Europe. The companies taking part in the Go for Israel part of the Sachs ELSCEO forum will be leading Israeli companies in the fields of MedTech, Biotech, Pharmaceuticals, Diagnostics, and Digital Health.

GENERAL INFORMATION

The registration desk will be open from 7.30am on February 25th, although you are welcome to join the event at any time. Please collect a copy of the agenda for information on timing and room allocation for each session.

Networking at the summit is facilitated by our online One-2-One meeting system, which is available to all participants. The One-2-One meetings are being held in La Plaza A & B and London A & B. Please bring with you a copy of your diary. Should you have any queries about your schedule, the Sachs team situated by the meeting tables is available for your assistance.

Wireless Internet connection is available throughout the venue for the duration of the event. Please ask for an access code at the registration desk.

There will be networking lunch, reception, and coffee stations set up in the rooms throughout the event.

REQUEST FOR PRESENTATIONS

Please use the agenda to mark off presentations that you are interested in and email your request to Silvia@sachsforum.com after the conference. We will endeavor to send you the requested presentations as soon as we have been granted permission to do so by that specific presenter.

Please note that we DO NOT have copies of the slides that are shown during the conference.
EVENTS DIARY

For the regular updates, sponsorship, presenting and attending opportunities and further information regarding any of our future events, please contact Silvia Kar on Silvia@sachsforum.com.

5TH ANNUAL IMMUNO-ONCOLOGY BD&L AND INVESTMENT FORUM
31ST MAY 2019 • WALDORF ASTORIA CHICAGO HOTEL • USA

Taking place on the first day of ASCO, the 5th Annual Immuno-Oncology BD&L and Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering, funding and investment. The event will focus on biotech partnering and investment giving you an excellent opportunity to network with executives from top pharma, biotech companies, and investors. We expect around 250 delegates and about 30 presentations by listed and private biotechnology companies seeking licensing & investment.

7TH ANNUAL MEDTECH & DIGITAL HEALTH FORUM
24TH SEPTEMBER 2019 • CONGRESS CENTER BASEL • SWITZERLAND

This year we will be holding our 7th Annual MT&DH Forum on the 24th of September, a day before our 19th Annual BEF, at the Congress Center Basel. The programme is designed to highlight the latest industry developments and showcase emerging and innovative technology companies seeking finance and partnerships. The delegates are comprised of Healthcare, MedTech, Healthcare IT and Digital Health companies as well as consultants, bankers and corporate & financial investors. We expect over 250 delegates and 25 presenting companies, plus around 20 presentations by seed companies.

19TH ANNUAL BIOTECH IN EUROPE FORUM
25TH - 26TH SEPTEMBER 2019 • CONGRESS CENTER BASEL • SWITZERLAND

The 19th Annual Biotech in Europe Forum is recognised as the leading international stage for those interested in investing and partnering in the biotech and life science industry. This highly transactional event draws together an exciting cross-section of early stage/pre-IPO, late stage and public companies, with leading investors, analysts, money managers and pharma licensing executives. We expect over 700 delegates and 100 presenting companies with additional 20 brief presentations by seed companies.

Supported and designed by leading figures within Europe’s pharmaceutical and biotech industry, the forum will be held for the sixth time in Basel to be close to the largest biopharma hub in Europe and the Congress Center provides meeting space capable of handling several thousand One-2-One meetings as well as significant exhibition space.

3RD ANNUAL NEUROSCIENCES INNOVATION FORUM
12TH JANUARY 2020 • MARINES’ MEMORIAL CLUB, SAN FRANCISCO • USA

Building on the success of our previews forums we are pleased to announce the 3rd Annual Neurosciences Innovation Forum for BD&L and Investment in Therapeutics and Technology to take place at the Marines’ Memorial Club, San Francisco, 12th January 2020, a day before the JP Morgan meeting.

ONLINE ONE-2-ONE MEETING SYSTEM AVAILABLE AT ALL SACHS EVENTS

In order to offer the best possible provision for networking opportunities and dealmaking Sachs Associates provides delegates access to our online One-2-One meeting system, allowing you to set up, accept or decline private One-2-One meetings with other conference attendees. These meetings last for 20 minutes in duration. Individual passwords and logins are provided to allow immediate access and ensure full security.
Emerald Health Pharmaceuticals, Inc.
Jim DeMesa
CEO

Dr. DeMesa is a former practicing physician and has 29 years of experience in biotech leadership, product development, clinical and regulatory management, and partnerships with pharmaceutical, biotech, and medical device companies. He has raised more than $150 million to advance product development into clinical stage, regulatory approval, and commercialization. Dr. DeMesa is the former CEO of two public biotech companies: Migenix and GenSci Regeneration Sciences (now part of Integra Lifesciences), and currently serves as director for two biotech companies: OncoSec and Induce Biologics. Previously, he was Vice President, Medical and Regulatory Affairs at Biodynamics International (now part of RTI Surgical) and Bentley Pharmaceuticals (now part of Teva Pharmaceuticals). Dr. DeMesa received a BA in chemistry, MD, and an MBA from the University of South Florida.

Euronext
Søren Bjønness
Director – Switzerland Representative

Søren Bjønness is Director and Switzerland Representative for Euronext, supporting Swiss Tech companies and tech ecosystem. He started his career in 1988 in the Royal Norwegian Navy, where he became a Second Lieutenant. His career includes environmental management, corporate banking, securitization and management buy-outs at UBS, Private Equity at 3i, corporate incubation at Sulzer, venture capital at New Value, Corporate Finance and Capital Markets at PwC. Søren holds a Degree in Leadership, Organisation, Finance and Economic Policy from the University of Fribourg and completed a doctorate in Leadership and Change in SMEs at the University of Basel.
SPEAKERS

**NxR Biotechnologies GmbH**

**Alain Vertès**
Managing Director

Dr. Vertès is Managing Director at NxR Biotechnologies, a boutique global consulting firm based in Basel, Switzerland, where he advises clients on strategy, business development, in/out-licensing, entrepreneurship and investment. He brings to his role extensive experience in the pharmaceutical and industrial biotechnology sectors, in Europe, North America and Asia and in different functions including research, manufacturing, contract research, and strategic alliances. NxR’s track record comprises projects with big phamas, biotechs, generics companies, financial investors, CROs, academia, and start-ups. Active in alliance management for Mesoblast, prior to NxR Biotechnologies Dr. Vertès held positions of increasing responsibility in pharmaceuticals at Lilly and Pfizer, as well as at Roche where he notably led through an external innovation partnering function the global cell therapies strategy and implementation team in 2007-2010. In addition, he has worked in petrochemicals at Mitsubishi Chemical Corporation, public research at the Institut Pasteur Paris and RITE/Kyoto, contract research at Battelle Memorial Institute and PPD/BioDuro, and has done consulting for the Australian Strategic Policy Institute. With a focus on innovation commercialization, he has been a key player in the evaluation, selection, deal making, implementation and alliance management of numerous novel products and emerging technologies.

Dr. Vertès received his M.Sc. degree from the University of Illinois at Urbana-Champaign, his Ph.D. from the University of Lille Flandres Artois and is a Sloan Fellow from London Business School (MBA/M.Sc.). Dr. Vertès is the lead editor of several science and strategy books in the fields of regenerative medicine and sustainable chemistry.

**Roche Venture Fund**

**Anja Harmeier**
Investment Director

Dr. Harmeier is a member of the board of directors of Entrada Therapeutics, Macrolide Pharmaceuticals, Minoryx Therapeutics and NMD Pharma.

Dr. Harmeier has experience in various roles in academic research, as an entrepreneur and in drug development at F. Hoffmann- La Roche. She led various programs using different modalities in the areas of neuroscience and rare metabolic and hematologic diseases.  

Dr. Harmeier holds an MSc in Biology from the Technical University of Munich, Germany and a PhD from the Free University of Berlin, Germany in Biochemistry. In addition, she received her MBA with a focus on healthcare management from Instituto Empresa (IE) in Madrid, Spain.

**Novartis Venture Fund**

**Anja König**
Managing Director

Dr. Anja König is the Global Head of the NVF in Basel, Switzerland. Previously, she was a Managing Director at NVF investing in Switzerland, U.K. and the rest of Europe as well as Asia/Pacific. Prior to joining NVF, she was an Associate Partner at McKinsey and Company in New York, where she worked with healthcare companies in the US, Europe and Emerging Markets. Anja holds a PhD in physics from Cornell University. She is active in the Swiss startup ecosystem and is a member of the board of the University of Zurich Life Sciences Fund, the evaluation panel of the Bridge Grant POC program of the Swiss National Science Foundation and the CTI, the selection committee of BaseLaunch and serves as a coach with the ETH Pioneer Labs program.
Jefferies International
Ankit Pareek
SVP, Healthcare Investment Banking

Ankit Pareek joined Jefferies in September 2010 and currently is a Senior Vice President in the Global Healthcare Investment Banking Group at Jefferies and is based in London. He covers Biotechnology companies with a primary focus on innovative companies in Europe. Mr. Pareek has over 10 years of investment banking experience and has executed transactions for biotechnology, pharmaceutical, medical technology, and healthcare services companies. Since joining Jefferies, Mr. Pareek has led the execution of more than 30 transactions including IPOs, Follow-on financings and M&A. Prior to joining Jefferies, he was employed at Goldman Sachs and UBS Investment Bank. Mr. Pareek completed his MBA (Finance) in 2007.

Seventure Partners SA
Annegret de Baey
Venture Partner

Annegret de Baey-Diepolder is a Venture Partner at Seventure Partners SA, a leading international investor in the microbiome sector. Formerly she was co-founder and CEO of RNA-based immunotherapeutics company Rigontec GmbH, now Merck & Co., Inc..

As a life science industry consultant and former partner at private equity and venture capital companies TVM Capital and Gimv NV, she brings almost 20 years of experience in the life science and venture capital sector. Prior to joining the VC industry, she led a research group developing therapeutic vaccines at Micromet AG, now Amgen Inc..

Annegret de Baey-Diepolder is trained as an MD, and worked on her specialization in Dermatology and Allergology at the department for Dermatology at academic hospital of the LMU in Munich.

Genclis SA
Bernard Bihain
CEO

After receiving his Doctorate in Medicine from the Free University of Brussels in 1984, Bernard achieved a surgery internship. In 1988, he worked at Columbia University, NY as a Postdoctoral Fellow. He then took a position as Assistant Professor of Physiology at the University of Louisiana, New Orleans. He was awarded the position of Research Director at INSERM, France in 1992 and became Professor and Chairman of the Dept of Biochemistry, University of Rennes. He then undertook the position of VP at Genset San Diego, later acquired by Merck-Serono. Prof. Bihain later became CSO of Valigen, New York.

He has actively contributed to the emergence of genomic technologies, as of in 2007, he discovered and patented the concept of Transcription Infidelity.

His pragmatism, stemming from his experience as a surgeon, powers Genclis’s science projects.

Prof. Bihain has authored over 50 publications and his studies are cited in more than 6000 scientific articles.
High-Tech-Gruenderfonds Management GmbH

Bernd Goergen
Partner

Dr Bernd Goergen, Partner, has been a part of High-Tech Gründerfonds’ Life Science Team since early 2008. He holds a PhD in biology and is a certified biotech analyst with the German Association for Financial Analysis and Asset Management (DVFA). He brings with him five years of research experience in the field of virology and immunology and seven years in international diagnostics marketing for German and international companies. Between 2000 and 2007, Dr Goergen also acquired extensive knowledge in M&A and capital market deals while working in the investment banking division of a major German bank.

Equillium, Inc.

Bruce Steel
Co-Founder, Director, President & CBO

Bruce is a co-founder, Director, and President and Chief Business Officer of Equillium (Nasdaq: EQ), a leading biotechnology company leveraging deep understanding of immunobiology to develop products for severe autoimmune and inflammatory disorders. He is also the founder and Managing Director of BioMed Ventures, the strategic investment arm of BioMed Realty. Since founding BioMed Ventures, Bruce has directed investments in over 30 biotechnology companies including Auspex, AnaptysBio, NeoTract and Receptos. Prior to co-founding Equillium, Bruce was co-founder and CEO of Rincon Pharmaceuticals, a genetic engineering biotechnology company, until its acquisition in 2008; previously he was Chief Business Officer at Anaphore and Head of Corporate Development at Ambit Biosciences. Bruce serves on the Board of Directors of Breathe Technologies and Aegea Medical, and is a board observer for a number of other private companies.

Bruce received his Bachelor of Arts degree from Dartmouth College and Master of Business Administration degree from the Marshall School of Business at the University of Southern California, and he holds the designation of Chartered Financial Analyst.
Oscine Therapeutics/ ARCH Venture Partners
Christina Trojel-Hansen
CEO/ Entrepreneur in Residence

Christina Trojel-Hansen, Ph.D., is CEO of a pioneering CNS focused cell therapy start-up, Oscine Therapeutics and Entrepreneur in Residence with ARCH Venture Partners. Christina led the launch of Oscine as investor at Novo Holdings, a leading healthcare investment firm committed to helping exceptional scientists build the next generation of healthcare companies. During her time at Novo, Christina has been spinning out several projects. Prior to joining Novo Holdings, Christina served as Senior Business Development manager in Novozymes’ Business Creation and M&A division leading teams focused on building new strategic platforms. Additionally, Christina has worked as patent agent at Zacco and as business analyst at Lux Research advising leading tech companies on a range of issues related to emerging technologies and business development. Christina has also been serving as start-up mentor at Indiebio (CA) and Breakout Labs (CA).

Christina has a background in the field of nanobiotechnology and cancer drug discovery. She completed her post-doctoral training at the leading European cancer Centre, Institute Gustave Roussy (INSERM) within the field of immuno-oncology. Christina holds a PhD from University of California, Berkeley and an MSc from the iNANO Centre at University of Aarhus.

Christina has received several awards and she was in 2017 nominated as one of Denmark’s top business talents.

Boston Pharmaceuticals, Inc.
Constantine Chinoporos
CBO

Constantine joins Boston Pharmaceuticals from Sanofi, where he was Vice President and Chief Licensing Officer, responsible for the global business development function since 2014. In addition, the North American and European regional Business Development teams reported to him. Some of the notable transactions he was directly responsible for included Sanofi’s $2.5 billion Immuno-Oncology pact with Regeneron, acquisition of the Rx to OTC rights for Cialis from Eli Lilly, and the purchase of Priority Review Vouchers from Biomarin and Retrophin.

Constantine brings extensive experience in Business Development with nearly 20 years of working in external innovation-focused roles in the biotech and pharma industries. He joined Sanofi following its acquisition of Genzyme in 2011, and assumed the role of regional head of Business Development for Sanofi’s North American Pharmaceutical division. Prior to this position, he was a Vice President in Genzyme’s Corporate Development group, which he joined in 2001.

Before Genzyme, Constantine served in various capacities at Eli Lilly and Company over a twelve-year period, including roles in Corporate Finance & Investment Banking as well as the Office of Alliance Management.

Constantine received an undergraduate degree in History as well as an MBA from Cornell University.
BeiGene, Ltd.

Corinne Venot
Senior Director Business Development

Biologist by training with a PhD from the University of Pierre & Marie Curie in Paris and a Master in biotech & pharma management from ESCP-EAP Paris. She has always been focused in the Oncology field, taking various positions from marketing, early drug discovery, R&D partnering to Business Development & Licensing. Joining Aventis, she was team leader for 8 years in oncology drug discovery projects, moving forward projects from target identification until preclinical candidate, major accomplishment was towards IGFIR project developing small molecule as well as antibody. During 8 years within Sanofi Oncology Division, as director of oncology business opportunities, she was specialized in preclinical/discovery assets with an emphasis on oncobiologics including antibody drug conjugates. She has been playing a major role in building the following licenses and partnerships: in-licensing p53/mdm2, small molecule inhibitor from Ascenta/Univ of Michigan; Dana Farber/Belfer Institute, strategic research collaboration; in licensing of antibody products for ADCs from Oxford Biotherapeutics; Caprion Target identification license & research collaboration; Algeta research collaboration for Thorium RadiolImmunoTherapy; several technology deals to build ADC next generation (Innate Pharma BTG technology, Catalent SMART Tag technology, Glykos new linkers, Avipep small format). Within the Immuno-Oncology space she has been playing a major role in building the following licenses and partnerships: in-licensing p53/mdm2, small molecule inhibitor from Ascenta/Univ of Michigan; Dana Farber/Belfer Institute, strategic research collaboration; in licensing of antibody products for ADCs from Oxford Biotherapeutics; Caprion Target identification license & research collaboration; Algeta research collaboration for Thorium RadiolImmunoTherapy; several technology deals to build ADC next generation (Innate Pharma BTG technology, Catalent SMART Tag technology, Glykos new linkers, Avipep small format). Within the Immuno-Oncology space she has been playing a major role in building the following licenses and partnerships: in-licensing p53/mdm2, small molecule inhibitor from Ascenta/Univ of Michigan; Dana Farber/Belfer Institute, strategic research collaboration; in licensing of antibody products for ADCs from Oxford Biotherapeutics; Caprion Target identification license & research collaboration; Algeta research collaboration for Thorium RadiolImmunoTherapy; several technology deals to build ADC next generation (Innate Pharma BTG technology, Catalent SMART Tag technology, Glykos new linkers, Avipep small format).

She moved to Servier in 2016, to lead the oncology portfolio licensing activities within the BD&L department. During here time at Servier, she has put in place the Pieris research collaboration and license agreement covering 8 imuno-oncology bispecific antigens, 2 research collaboration and license agreements on undisclosed targets with Vernalis and the WEHI, as well as a technology license with Transgene for CART Cell therapy. More recently she actively contributed to the Shire Oncology portfolio acquisition recently joined Beigene, as Senior Director BD&Licensing

Asceneuron SA

Dirk Beher
Founder & CEO

Dirk Beher is the Chief Executive Officer, a Founder and a Member of the Board of Directors of Asceneuron SA. Since its inception he has strategically positioned Asceneuron as an emerging leader in the field of orally bioavailable drugs for treating tauopathies. Under his leadership the company has raised to date over CHF 40 million from leading venture capital firms and successfully moved a novel modifier of tau pathology into the clinic.

Dirk brings more than 25 years of experience in the field of Alzheimer’s disease / neurodegeneration and spent over 19 years in pharmaceutical drug discovery including senior research positions around the globe at Merck Sharp & Dohme (Merck & Co.), Amgen and Merck KGaA. Dirk holds a Ph.D. and a Diploma (M.S.) in Biology from the Ruprecht-Karls University Heidelberg, Germany. He is an inventor of seven patents and author of 49 peer-reviewed publications and reviews.

MSQ Ventures

Echo Hindle-Yang
Founder & CEO

Echo is on a mission to make technology accessible by bridging the gap between western companies and Chinese corporations and investors. She is unique in that she has 20 years of experience in cross-border transactions for fortune global companies, such as IBM, Lenovo, and J&J. In recent years, she is focused on bridging healthcare industry globally and has been worked with 100+ healthcare companies including the global top pharm/medical device companies. She holds an MBA from Duke University and serves on DukeNY board.
PDC*line Pharma SA

Eric Halioua
President & CEO

Serial entrepreneur that combines strong managerial, technological, product development and fund-raising experience in biotechnology. He raised more than €90 million over the course of his career and has had numerous successes in the sale and initial public offering of biotechnology companies.

Eric Halioua is President and CEO of PDC*line Pharma, a clinical-stage biotech company that develops a new class of therapeutic cancer vaccines based on a line of Plasmacytoid Dendritic cells (PDC*line).

He is as well Board member of the biotechnology company Bioxodes (Belgium), HairClone (UK), VitriCell (Belgium) and member of the strategic advisory board of Innobi-chips (France).

He was CEO at Promethera Biosciences a biotechnology company that develops cell therapy products to treat liver diseases. He is co-Inventor of the first GMP approved mobile manufacturing unit for cell therapy (WO 2014049151 A).

Eric is as well co-founder of three biotechnology companies called Myosix, Murigenetics and Digital-Orthopaedics:

- Myosix is a tissue engineering company specialising in musculoskeletal cells culture used in the regeneration of the heart muscle. The company has been bought by Genzyme mid-2002.
- Murigenetics is a Biotechnology company developing therapies for genetic disorders.
- Digital Orthopaedics is a Digital Health company providing access to a comprehensive Clinical Decision Support System for musculoskeletal pathologies.

Eric was also a Board Member of a French public biotechnology company called Valneva, which specializes in the development and commercialisation of vaccines and monoclonal antibodies.

He was as well principal of the international life sciences practice of Arthur D. Little based in Paris and Boston during 11 years. He has led work in the areas of strategy, Due Diligences, M&A and technology & innovation management for biotechnology and pharmaceutical companies. He worked for IsoHealthcare Group (eventually acquired by the Monitor Group) as a Senior Consultant where I focused on leading healthcare and life sciences issues. Eric also worked as a strategic marketing manager for the “Centre Européen de Bioprospective” and as project leader in the corporate R&D centre of Astra-Zeneca in UK.

Eric holds two master degrees (DEA and Magistère) in Pharmacology and Molecular Biology and a MBA from ESSEC business school (Paris, France), with an advanced degree from the Health Care ESSEC chair.

TargImmune Therapeutics AG

Esteban Pombo Villar
CEO

Dr. Esteban Pombo-Villar is the Chief Executive Officer of TargImmune Therapeutics, and has 30 years of experience in leading biopharmaceutical R&D, business development and alliance management. Previously he was Chief Operations Officer (COO) for Oxford BioTherapeutics, and a Member of their Boards of Directors. He was responsible for the development data and manufacturing activities of their lead antibody and antibody-drug conjugate projects and their collaboration projects. Prior to joining Oxford BioTherapeutics, Dr. Pombo-Villar was at Novartis and Sandoz for over 23 years, the last 12 years engaged in Business Development and Alliance Management, most recently as Head of Alliance Management at the Novartis Institute for Biomedical Research (NIBR), for alliances in all therapeutic areas up to proof-of-concept in man. Prior to that he led Medicinal Chemistry efforts in the Neuroscience group at Chemistry Expert, and was Laboratory Head and Chemistry Project Leader for multiple projects. He obtained a PhD, MSc and BSc in organic chemistry from the University of Warwick (UK), was visiting researcher at the University of Newcastle upon Tyne (UK) and completed post-doctoral studies at the ETH in Zurich. Dr. Pombo-Villar is a Fellow of the Royal Society of Chemistry, and member of several scientific societies, and has completed executive business studies at IMD (MTE, Lausanne), Harvard Business School (US), and the Tuck School of Business (Dartmouth, US). Dr. Pombo has been on the faculty of the European Course for Biobusiness Development (University of Basel and ETH Zurich, 2007-2009), lectured in many conferences and workshops and is a member of the Licensing Executive Society.
**PharmaVentures Ltd.**  
**Fintan Walton**  
CEO

In 1992 Dr Walton co-founded CONNECT Pharma, a predecessor company to PharmaVentures focused on assisting pharmaceutical and biotechnology companies worldwide in all aspects of deal making. In 1997 this company became PharmaVentures.

Since its inception, PharmaVentures has worked with blue chip clients on a global basis, delivering more than 700 assignments for companies in 38 countries. Clients have included major pharmaceutical and biotechnology companies as well as diversified chemical corporations, medical device, generic and OTC companies. Its clients have included major banks, investment/merchant banks, and private equity and venture capital groups.

In 1996 he also founded PharmaDeals, the leading database and publishing business related to dealmaking. Thousands of customers from around the world have either bought or subscribed to these PharmaDeals publications. PharmaDeals was sold to IMS Health in Aug 2012.


---

**Inserm Transfert Initiative /Sofimac**  
**François Thomas**  
Venture Partner

Venture capitalist: former partner at Atlas venture and president Inserm Transfert Initiative; presently venture partner at Sofimac

Medical oncologist: former assistant prof Gustave Roussy (Villejuif) and fellow US National Cancer Institute

Biotech and pharma exec: former VP clinical development of Ipsen

Consultant: president of Bioserve Ltd

Former or present Non exec-director of about 25 biotech companies; presently member of the board of Gamamabs, Integragen, Cardiawave, Enyo, Eyevensys, Step Pharma, Inotrem, Sensorion.

---

**Medicxi**  
**Giovanni Mariggi**  
Partner

Giovanni is a Partner at Medicxi and has been with the firm since its inception in 2016. Prior to Medicxi, Giovanni was a Principal at Index Ventures for four years, having joined in 2012. He led Medicxi’s investment in Obseva and currently serves on the boards of a number of portfolio companies, including Gadeta, SuperX, Kymo Therapeutics and Janpix.

Prior to joining Index, Giovanni was at Cancer Research UK’s London Research Institute (now the Crick Institute) where he conducted research on vascular biology and angiogenesis, whilst also delivering competitive intelligence projects in oncology as an independent consultant to various biopharma.

Giovanni received a BSc in Biochemistry from Imperial College London and a PhD in Biochemistry and Molecular Biology from University College London.
InCarda Therapeutics, Inc.
Grace Colon
President & CEO

Dr. Colón brings over 25 years’ experience in biopharma, genomics, healthcare and industrial biotechnology. In addition to her role at InCarda, she is a senior advisor at New Science Ventures (where she was a Partner from 2014-2016) and serves on the board of directors of ProterixBio (Executive Chairman; formerly CEO). Paradigm Diagnostics, PerceptiMed and Cocoon Biotech. She is also a member of the Advisory Board of the Miller Center for Social Entrepreneurship at Santa Clara University.

Previously, she co-founded Pyranose Biotherapeutics, a biologics discovery platform company. She was also founding President of the Industrial Products Division at Intrexon Corporation, where she established a new division focused on leveraging synthetic biology for bioindustrial applications such as biofuels and renewable chemicals. Prior to Intrexon, she was head of Clinical Operations for Gilead Sciences, where she was responsible for global execution of clinical trials. She also created and led both the Alliance Management and Commercial Strategic Planning groups. Prior to Gilead, she was VP, Corporate Planning at Affymetrix, where she was responsible for strategic planning and project management and where she also served as COO for the International Genomics Consortium, a non-profit medical research organization focused on cancer genomics. Earlier in her career she was a engagement manager with McKinsey & Co., where she served clients in healthcare, biotech, high tech and venture capital. She was also an engineer with Merck & Co. in France and in Rahway, NJ.

Dr. Colón received her Ph.D. in chemical engineering from the Massachusetts Institute of Technology, where she was an NSF Fellow. She also holds a B.S. degree in chemical engineering from the University of Pennsylvania, where she was a Benjamin Franklin Scholar.

ABIVAX
Hartmut Ehrlich
CEO

Physician and entrepreneur with 30+ years in the bio-pharmaceutical industry, having lived and worked in the US, The Netherlands, Germany, Switzerland, Austria and France.

Since 2013, CEO of Paris-based ABIVAX, which is targeting the immune system to develop novel treatments for inflammatory and viral diseases as well as cancer. Following exciting Phase 2a clinical results in ulcerative colitis (UC) in Sep. 2018, the company focusses on driving its lead compound ABX464 into Phase 2b clinical trials in UC and HIV, as well as clinically exploring additional inflammatory indications (e.g. Crohn’s disease, rheumatoid arthritis, multiple sclerosis).
VAXIMM
Heinz Lubenau
COO

Heinz Lubenau co-founded VAXIMM in 2008 and currently serves as Chief Operating Officer leading all the development activities of the Company. Prior to this, 2003-2008, he was Global Project Manager Biosimilar G-CSF and Head of Preclinical and Clinical Development at BioGeneriX AG, where he led the development work of the first biosimilar G-CSF Ratiogranstim® from preclinical studies through European marketing approval and launch and of the 2nd generation G-CSF Lonquex from project implementation to clinical Phase 2. In 1994 he joined Servier Forschung und Pharmazeutwirkung GmbH as Junior Project leader and rose to Clinical Research Manager and Project Director Internal Medicine in 2001. In this role he was responsible for Servier Phase 1 to Phase 3 clinical trials in Germany, Austria and Switzerland for cardiology, diabetes and hypertension, including the registration trials of Preterax® and Procoralan®. At this time, he also led clinical project teams and was responsible for hiring clinical project staff. Heinz Lubenau gained his PhD in pharmacy from Johannes-Gutenberg-University, Mainz.

Forbion
Holger Reithinger
General Partner

Holger Reithinger holds a PhD in Biochemistry, which he obtained under the supervision of Prof. Dr. Arne Skerra; all in the department of Prof. Dr. Hartmut Michel (Nobel Laureate 1988) at the Max-Planck-Institute of Biophysics. As an undergraduate, Holger studied Molecular Biology/ Microbial Biology and Biochemistry at the Universities of Heidelberg and Munich. After his studies, Holger gained operational experience as a product development manager at Biometra/ Whatman Plc (now part of GE Healthcare). He started his career in Venture Capital in 1997 as an Investment Manager at Technologieholding VC GmbH which at that time was one of the leading German Venture Capital firm. Technologieholding was acquired by the 3i Group in early 2000, where Holger became a Director at its Germany’s healthcare practice. Following this assignment, he became Principal and later Partner at Global Life Science Ventures, a well-established life sciences-focused partnership with offices in Switzerland and Germany. Holger has served on the Boards of numerous life sciences companies including Epigenomics (IPO 2004), MBT (assets sold to Medigene AG), 4SC (IPO 2005), NeurogesX (IPO 2007), Fibrex Medical (assets licensed to Ikaria Inc.), Agendia BV, Santaris A/S (sold to Roche 2014), Curetis NV (IPO 2015), Cellinovo Group S.A. (IPO 2015) and Rigontec GmbH (sold to MSD 2017). Holger holds board seats at Allegra Therapeutics GmbH, catalYm GmbH, Gotham Therapeutics Inc. and Omeicos GmbH.

Lilly Asia Ventures
Ji Li
Venture Partner

Dr. Ji Li has more than 21years of business development, R&D and investment experience in the biopharmaceutical sector. He is currently Venture Partner at Lilly Asia Ventures (LAV), one of the most successful healthcare venture firms from China. Prior to LAV, Ji was Executive VP and Global Head of Business Development at BeiGene where he oversees the company’s partnering activities worldwide, including leading the landmark strategic transaction with Celgene that has transformed BeiGene into a fully integrated biopharmaceutical company. Prior to BeiGene, Ji served as VP of Business Development and Licensing at Merck, where he led the group that was responsible for BD activities of all late-stage inbound and outbound partnering opportunities globally. During this period, Ji has also served, on behalf of Merck, as member of the Board of Director for BeiGene. Prior to Merck, Ji was Executive Licensing Director, External R&D at Amgen where he led the company’s product search and evaluation BD team. Earlier in his career, Dr. Li was key member of the Amgen research team discovered and validated the RANKL signaling pathway that has led to the successful development and commercialization of Denosumab, the current standard of care therapy for various bone loss indications with annual sales of about $4 billion. Ji obtained his B.S. in Pharmacology from Shanghai Medical University and Ph.D. in Neuroscience from Mount Sinai School of Medicine in New York.
AbbVie, Inc.
**Joachim Vogt**
Director, Search & Evaluation, Western Europe

Joachim Vogt is Director Search & Evaluation Western Europe at AbbVie. He is responsible for the identification of European business opportunities across all indications and technologies of interest for AbbVie and serves as key contact for European partners, including academic institutions, biotech companies, venture capital, governments and non-profit organizations.

Joachim spent more than 15 years in the pharmaceutical and biotech industry in BD and research roles. He gained broad experience in the areas of in- and outlicensing of preclinical and clinical projects as well as research technologies. Before joining AbbVie, Joachim was Director of Early Stage Partnering at Roche, served as Senior Manager at Wilex AG and was Head of IP Licensing at the tech transfer office Bayerische Patentallianz. Joachim holds a diploma in chemistry and received his PhD in protein crystallography at the University of Freiburg.

LSP
**Jörg Neermann**
Partner

Jörg Neermann, PhD, joined LSP in 2007 as Partner. Jörg’s prime focus and responsibility within LSP is to invest in unlisted securities. Prior to joining LSP, Jörg was the Managing Director of Deutsche Bank’s DVC, where he ran its healthcare investment franchise. Previously, he worked at Atlas Ventures in Germany where he also invested in the healthcare sector. Jörg brings a strong scientific background and hands-on finance and investment expertise to the LSP team. He has been appointed a Director at a large number of companies, all of which he has helped with his scientific expertise, biotechnology experience and global networks. Among others, Jörg is currently a Director at Probiodrug, a German biotech company that went public on Euronext Amsterdam in 2014 and is active in the development of novel, disease modifying therapeutics against Alzheimer’s disease. Jörg holds a Master’s degree and a PhD in Biotechnology from the Technical University in Braunschweig and MIT in Cambridge, US.

MGC Pharmaceuticals Ltd.
**Jonathan Grunfeld**
CSO

Certified in Israel, with clinical experience in at the M.D. Anderson Cancer Center, Dr. Grunfeld has spent the past twenty years focusing on Neuro-Oncology, with a focus since 2010 on Cananbis as a treatment for oncological palliative care. He has directly been involved in the licensing and care of over 3000 medical cannabis patients in Israel, giving him a unique insight into questions of dosing, patient groups and developing treatment methodology.
**KPMG**

**Juemin Zhu**  
Head of China Desk Switzerland

Juemin is Head of China Desk at KPMG Switzerland. With a broad set of experience in strategy and M&A consulting, she bridges and leads cross-border investment and business between Switzerland and China. Juemin is well connected and positioned in the Swiss-Chinese business community. She has acquired 12-years of comprehensive experience with international projects in 14 countries. Prior to joining KPMG, Juemin worked for Fosun, a Chinese international conglomerate and investment company, as Associate Director for European Investments. She holds a Master degree in Mechanical Engineering from Karlsruhe Institute of Technology, Germany.

**Gimv**

**Karl Nägler**  
Partner

Karl Nägler joined Gimv in 2011.

Having started his professional career in 2002 at Atlas Venture in London and Munich, he later joined Ventech, a Paris-based venture capital firm focused on Europe and China.

Karl has a successful track record in early and later stage Life Science investing and was instrumental in the formation, financing and/or exit of several start-ups across Europe, including U3 Pharma (acquired by Daiichi Sankyo), Nitec Pharma (acquired by Horizon Pharma, HZNP:US), Egalet (EGLT:US), Funxional Therapeutics (acquired by Boehringer Ingelheim) and Themis.

Since he joined Gimv, Karl has led investments into Prosonix (acquired by Circassia, CIR:LN), Covagen (acquired by Johnson & Johnson, JNJ:US), Biom’up (BUP:EPA), Topas Therapeutics, Breath Therapeutics and Imcheck Therapeutics and has represented Gimv on the boards of those companies as well as on the board of Actogenix (acquired by Intrexon, XON:US).

Previously, Karl had worked as a Scientific Fellow at the CNRS for Neurochemistry in Strasbourg (France) and holds a PhD in the area of molecular neurobiology from the Max-Delbrück-Center for Molecular Medicine (Berlin) and a Diploma in Biology from the Free University of Berlin.
Ekaterina (Katya) Smirnyagina is a partner with the Capricorn Health-Tech Venture Fund. Prior to this she was with Alta Partners, a US healthcare focused venture firm. Her current and past board memberships include Adocia (Euronext: ADOC.PA), ConfoTherapeutics NV, HalioDx SA, iSTAR Medical SA, Nexstim plc., Ablynx, Cerenis Therapeutics, Innate Pharma and Kiadis Pharma. Katya is also on the board of InvestEurope (fka EVCA) and is the current Chair of its VC Council. Previously she has worked in business development at Genset S.A. and management consulting at the Mitchell Madison Group. Katya was a postdoctoral fellow in microbiology & immunology at the Stanford University School of Medicine and holds a Ph.D. in cellular & molecular biology from the University of Wisconsin-Madison and a B.Sc. in biochemistry from Moscow State University.

Keno Gutierrez, PhD, MBA, joined the Healthcare team as an Investment Director in 2017. Previously, he worked at Omega Funds, where he invested in public and private healthcare companies, participating in direct investments and secondaries. Before joining Omega in 2014, Keno was an associate at Piper Jaffray’s Healthcare Investment Banking group, advising biopharma and medtech companies on corporate finance, cross-border M&A and licensing. Prior to joining Piper Jaffray in 2010, he spent four years as a consultant at IMS Health, advising pharma clients on portfolio strategy and commercial operations. Keno is a Fellow of the Royal Society of Medicine, holds a PhD in Genetics from University College in London and an MBA from INSEAD. His research in lipid metabolism has been published in the top scientific journal Nature. Keno is based in Amsterdam.

Dr. Kevin Pan is a co-founder of Asieris Pharmaceuticals and has served as its president and CEO since Mach 2010. Asieris is a private, VC-backed biotech company based in China with an aspiration for the global market. Its leading clinical candidate is the first orally available MetAP2 inhibitor in a pivotal clinical trial in China and phase Ib trial in the US for treating non-muscle invasive bladder cancer. Before founding Asieris, Dr. Pan was a founding member of Hutchison MediPharma, a China-based biotech company current listed on London’ AIM and NASDAQ. He served as the senior director of drug discovery chemistry and IP at the beginning, and then led the company’s BD department with a successful track record of partnership deals with P&G, Merck Serono and Eli Lilly. Dr. Pan started his career in the pharmaceutical industry from R&D divisions at Pfizer (Groton, CT) and Johnson & Johnson (Spring House, PA). Dr. Pan received a BS degree in organic chemistry from Fudan University in Shanghai and a Ph.D. degree in bioorganic chemistry from Rutgers, the State University of New Jersey. He had been an adjunct professor at the School of Pharmacy of Jilin University in China from 2005-2010, and is currently members of the Bayhelix Group and Chinese Society of Clinical Oncology (CSCO).
EIT Health e.V.
Kurt Höller
Director of Business Creation

Since December 2015, Kurt is Director of Business Creation at EIT Health. He is leading the EIT Health Accelerator having supported more than 500 startups with close access to all leading players in health industry and a 15mio € budget per year. Within Innolife, the preparation consortium of EIT Health, Kurt was part of the Executive Committee as a spokesperson for all German academic partners.

From 2009 to 2015, Kurt has been the managing director of the Central Institute of Healthcare Engineering (ZIMT) at Friedrich-Alexander-University (FAU). Since then he has gone on to found and direct several other companies: CiNNAMED GmbH (2013, CEO and co-founder), Portabiles GmbH (2014, CFO and co-founder), and HOELLER ELECTRONIC GmbH (CEO in 2015). Since May 2015 he has been a member of the city council in Erlangen and member of the supervisory board of ESTW AG.

After attaining his Diploma of Electrical Engineering at Friedrich-Alexander-University (FAU), he gained his Doctorate at FAU with research stays at (TUM), and Johns Hopkins University (JHU), USA. His research activities focused heavily on health innovation, with his thesis on “Novel Techniques for Spatial Orientation in Natural Orifice Transluminal Endoscopic Surgery (NOTES)”. He has published 24 journal articles and conference papers. Kurt went on to earn an MBA with focus on Entrepreneurship at Deggendorf Institute of Technology (THD) with a research stay at Santa Clara University in the Silicon Valley.

Astrazeneca
Lars Gredsted
Associate Director, Partnering & Strategy

Lars Gredsted is associate Director Partnering & Strategy at MedImmune in Cambridge, UK. His responsibilities include both in and out-licensing of therapeutics and enabling technologies with a focus on oncology and platform technologies. In addition, he works with the local UK and wider European ecosystem to develop relationships and establish strategic collaborations with universities and other leading research institutions.

Before joining Medimmune he was a partner at the Innovations division of the Wellcome Trust, a global biomedical charity, working with investments in discovery & development of novel therapeutics, medical devices and vaccines. In this role he was responsible for sourcing and transacting on new charitable investments as well as providing oversight of investments in the portfolio. He was a board director in Canbex Therapeutics and Acesion Pharma and observer on a number of other boards.

Before joining Wellcome he worked with in-licencing at Union Life Sciences in Oxford and as a management consultant with the Boston Consulting Group in Copenhagen.
Lubor Gaal, PhD is Senior Vice President and Head of Europe at Locust Walk, a global life science transaction firm with offices in Boston, San Francisco, Tokyo and Europe. Over the last 10 years, we have helped many Biopharma and MedTech clients find the right partner for their assets, access capital or identify new assets to strengthen their pipeline to position themselves for an IPO or trade sale. Lubor is responsible identifying the right partner and executing licensing, M&A and financing transactions for European biotechnology and pharmaceutical companies.

Lubor has been doing business development for biopharma companies in Europe and the USA for more than 20 years. Prior to joining Locust Walk, he was the Head of External Innovation and Licensing and a member of the R&D Management Committee at Almirall. From 2006 to 2015, Lubor held various senior BD positions at Bristol-Myers Squibb such as Global Head of Fibrosis, Neuroscience, Immunoscience and Head of Europe, Search and Evaluation. Before that, he held executive management roles at CNS company Neuro3d in France and for Immuno-Oncology company Vectron Therapeutics AG in Germany. In the US, Lubor was the Head of CNS and CV Licensing for Schering AG (now Bayer) in New Jersey and advised and transacted for biotechnology and pharmaceutical companies at Burrill & Co. in San Francisco, California.

Lubor has a B.Sc. in Neuroscience from the University of Sussex in the UK and a Ph.D. from the University of California at Berkeley, USA.

Lynn Durham
Founder & CEO

Lynn is a biotech entrepreneur and the founder of STALICLA. Driven by her lifelong involvement with the autism patient and research community, she co-developed the Databased Endophenotyping Patient Identification model to kick-start systems biology-based drug development in ASD. Over the last two years, she has secured capital and world class talent fostering the creation of STALICLA’s Drug Development team in Geneva and R&D computational systems biology unit in Barcelona.

Lynn has extensive experience in Business Development and has previously worked for the World Economic Forum, a leading Swiss venture capital firm, and startup accelerators in the lemanic area. She has also spent 5 years at the Faculty of Medicine at the University of Geneva. Lynn Durham holds a master degree in political sciences and economic history and Lynn holds a double degree in economic history and political sciences and a Master’s degree from Rouen Business School. Lynn also pursued a post-graduate degree in Drug Discovery and clinical Development at the Faculty of medicine of the University of Geneva.
**Johnson & Johnson Development Corporation (JJDC)**

**Maciek Drozdz**
Principal of Venture Investments

Maciek Drozdz is a Principal of Venture Investments for Johnson and Johnson Development Corporation (JJDC) and joined in 2017. Maciek is based in London at the Johnson and Johnson Innovation Centre.

Maciek has spent 10 years working in the Venture Capital and biotech industry. Most recently he served as a CEO of Antagonis Biotherapeutics, an immuno-oncology company in Graz, Austria. Previously he was investment manager at Entrepreneurs Fund LLP, investment director at MCI Bioventures and an analyst at Atlas Venture. Maciek has served on a number of boards of private and public companies across several countries.

Maciek received his Master’s Degree in molecular biology from the Adam Mickiewicz University in Poznan, Poland followed by a Doctorate at the University of Heidelberg in Germany. He has also worked as a Postdoc at the Friedrich Miescher Institute in Basel, Switzerland. Maciek holds an MBA degree from the Said Business School in Oxford. He lectured a course in “Innovation in Biotechnology” at Adam Mickiewicz University.

**IO Biotech ApS**

**Mai-Britt Zocca**
CEO

Mai-Britt Zocca is CEO of IO Biotech. She has participated in founding and co-founding of several biotech spinouts. She is a member of the BoD of VAR2 Pharmaceuticals and has held several executive positions in the industry. Mrs. Zocca holds a PhD in tumor immunology and a Master Sc. in Biochemistry receiving her PhD from the Institute of Medical Microbiology and Immunology, University of Copenhagen, and the NIH, National Cancer Institute, Maryland, USA.

Mai-Britt Zocca has more than 15 years of experience in translational immunology (Immuno Oncology) and has published more than 25 articles in peer reviewed international journals. Furthermore, she is an inventor of several patents.

Mai-Britt Zocca has focused her work on translational immunology especially for the development of immunotherapies for cancer diseases. She has been involved in several clinical studies and is also focused on biomarker discovery in immunotherapy. Participates in a taskforce consisting of several EU and US clinical departments and the FDA.

**AbbVie Ventures**

**Margarita Chavez**
Managing Director

Margarita is Managing Director at Abbvie Ventures. Margarita has lead investments in over a dozen biotech companies in the US and Europe and is responsible for AbbVie’s investments in Alector, Morphic Therapeutics, Palleon Pharmaceuticals, CARISMA Therapeutics, eFFECTOR Therapeutics, Jnana Therapeutics and Magnolia Neurosciences. Margarita brings over 20 years of dealmaking experience, with over a decade in biotech M&A and venture.

Margarita was previously a Director with Abbott’s Global Pharmaceutical Licensing & Acquisitions. Among others, Margarita was involved in the in-licensing of Elagolix, the acquisition of Immuvuen, and the acquisition of the Lupron franchise. Before joining Abbott, Margarita practiced as a corporate and securities lawyer in Silicon Valley with the firm of Brobeck Phleger & Harrison, advising in equity financings, M&A and IPOs.

Margarita currently serves on the Boards of the New England Venture Capital Association and the MidAmerica Healthcare Investors Network and on the Advisory Board of the Santa Clara University School of Law.
BioMedPartners AG
Markus Hosang
General Partner

Dr. Markus Hosang is a General Partner and Managing Director at the life sciences venture capital firm BioMedPartners in Basel. He has strong experience and broad knowledge in strategic and operational aspects of the VC business, as well as in pharmaceutical and diagnostics R&D. Before joining BioMedPartners, Dr. Hosang was a Venture Partner at MPM Capital, where he managed their European office and was co-responsible for their European deal flow. Previously, at Roche in Basel, he held several senior management positions of increasing importance in its global Pharma R&D organization, and was directly involved in major strategic transactions, including the acquisition of Genentech. Dr. Hosang obtained his Ph.D. in Biochemistry from the ETH Zurich. He serves on the boards of several biotech and medtech companies, many of which have already been exited highly successfully.

Novartis International AG
Markus Kalousek
Head of Pharma Search & Evaluation, Global BD&L

Markus is Global Head of Search & Evaluation for Novartis Pharma BD&L. He has 20 years leadership experience in various countries and functions (BD&L, M&A, Drug Development), with proven track record of successful development and in-licensing of innovative drugs. He has been key to developing one of Novartis’ most successful drugs ever, has built up a development organization abroad and has done eleven major transactions. Prior to working at Novartis, Markus had roles of increasing responsibility in small and mid-sized Biotech and Pharma companies. Before joining the Pharma industry, he studied Biochemistry, Molecular Biology & Pharmaceutical Medicine and did his PhD and PostDoc in Oncology research.

Symphogen A/S
Martin Olin
CEO

Martin Olin, EMBA, M.Sc., is a Danish national, born in 1969. He served on the Board of Symphogen in 2001-2008. Martin Olin joined the company in 2012 as Chief Financial Officer and was appointed Chief Executive Officer in 2016. Before joining Symphogen, Martin Olin was a senior partner with SLS Invest, a Scandinavian based healthcare focused private equity fund and he has held managerial positions in Novo Nordisk.

BioInvent International AB
Martin Welschof
CEO

Dr. Welschof is currently the CEO for BioInvent, Sweden. Martin brings significant senior executive experience in the biotech sector having launched and built successful businesses focused on drug development and drug discovery platforms. Before joining BioInvent, Martin Welschof was CEO of Opsona Therapeutics, Managing Director and co-founder of Affitech A/S in Oslo/Norway and Copenhagen/Denmark. Prior to joining Affitech A/S, Dr. Welschof was the Director of Technology at Axaron Bioscience AG, Heidelberg, Germany. During his period at Axaron he worked also in the parent company of Axaron Bioscience, LYNX Therapeutics Inc. in Hayward California. Martin holds a PhD in the field of recombinant antibody technology from the University of Bielefeld, Germany. Martin Welschof also serves at the board of UTR AS, Nextera AS and APIM Therapeutics.
Merck KGaA
Matthias Müllenbeck
Director, Global BD&L, Oncology

Dr. Matthias Müllenbeck is Director Global Licensing & Business Development Oncology at Merck Biopharma, responsible for designing and leading strategic partnering initiatives in the field of oncology and immuno-oncology.

Matthias has a track record of leading strategic licensing-, co-development, co-commercialization transactions and multi-asset portfolio acquisitions for various clinical- and pre-clinical-stage assets-, platform technologies-, and companion diagnostics. Matthias holds a PhD in immunology from the Humboldt-University of Berlin and a MBA from Kellogg-School of Management Chicago. Prior to joining Merck, Matthias worked as a scientific project leader at the Max-Planck Institute for Infectionbiology Berlin, Germany, and the Albert-Schweitzer Hospital in Lambaréné, Gabon.

Swiss Biotech Association
Michael Altorfer
CEO

Dr. Michael Altorfer is the CEO of the Swiss Biotech Association. He has more than 20 years of experience in the life science industry comprising both big pharma and smaller biotech organizations. As a member of the Executive Committee he supported the build-up of Polyphor Ltd in Allschwil in many different roles (Head BD&L, CFO, COO and CEO). Michael started his career as a scientist in pharmaceutical research at Sandoz, Ciba-Geigy (Summit, NJ, USA), and Roche. From 1996 to 2001 he held program management and line management roles at the investment bank UBS Warburg.

Michael studied Natural Sciences at the ETH and he obtained his Ph.D. in Chemistry under the supervision of Prof. Dr. H.-J. Hansen (University of Zurich) and Prof. Dr. K. Müller (Roche) and holds an MBA degree from the University of Rochester, NY, USA.

Pharmaleads SA
Michel Wurm
VP, Medical Affairs, Strategy & BD

Michel joined Pharmaleads in 2006 to head the corporate development and oversee preclinical and clinical developments of the Company’s products. He has extensive experience across all aspects of drug development, with a focus on clinical trials. Prior to joining Pharmaleads Michel was Corporate Development Director of French biotech Imaxio. He has also held international positions in Pharma companies (Novartis, Galderma), Biotech companies (Imaxio) and with CROs bringing several new chemical entities to registration.

Michel wrote the French version of the Investigator’s Guide to Clinical Research (Centerwatch, Boston, 2002).

Michel is a graduate from the School of Medicine of Clermont-Ferrand, France.
CoFeS China
Mirko Scherer
Managing Partner

Dr. Scherer is CEO of CoFeS China (formerly known as TVM China). CoFeS’ mission is to facilitate licensing, investments, and partnerships between innovative Western life science companies and Chinese investors and companies. Mirko is co-located in Hong Kong and Paris.

Previously he consulted for MPM Capital focusing on deal sourcing for MPM in Europe. Mirko was also a co-founder and partner at Ki Kapital which specialized in consulting in the life science industries.

Prior to working in the VC and advisory business, Mirko co-founded GPC Biotech (Munich and Princeton, NJ) and served as its Chief Financial Officer for a decade. GPC Biotech engaged in numerous pharmaceutical alliances with companies such as Sanofi Aventis, Boehringer Ingelheim, Altana (now part of Takeda), Yakult and Pharmion (now part of Celgene). At GPC, Mirko was responsible for all financial, legal, corporate communication and governance topics. He was instrumental in numerous capital raisings (venture capital stage, IPO and follow on offerings in Germany as well as on NASDAQ), licensing transactions, mergers & acquisitions and other strategic transactions. Over the last 20 years Mirko has established an extensive network in the European, Chinese, and North American pharma, biotechnology and venture capital industries. Prior to his time at GPC Biotech Mirko worked as a consultant at the Boston Consulting Group. He has served on the Board of the Frankfurt Stock Exchange as well as Quantapore Inc. and is currently a board member of the Stichting Preferente Aandelen Qiagen, and Aptorum Inc.

Mirko holds an MBA from Harvard Business School, Boston. He also earned a Doctorate in Finance from the European Business School in Oestrich-Winkel/Germany and a degree in business administration from the University of Mannheim/Germany.

F. Hoffmann-La Roche Ltd.
Miro Venturi
Global Head Diagnostics Biomarkers

After receiving his PhD from the Max-Planck Institute of Biophysics in Frankfurt, Miro specialized in molecular medicine, virology and immunology at the National Institutes of Health, Bethesda, USA. In 2002, Miro joined the pharmaceutical industry as a Biomarker Laboratory Head and project team representative at Pharmacia Corp (later Pfizer Inc.) at the Oncology R&D site located in Nerviano, Italy. In this role, he initially established the biomarker laboratories and actively contributed to the development of numerous oncology programs focusing on small molecular weight kinase inhibitors, including the early development of sunitinib (Sutent) as well as research and exploratory biomarker strategies for several preclinical programs, from lead optimization until PoC clinical studies. In 2005, Miro was invited to join the faculty of the University “Vita Salute San Raffaele” in Milan as Adjunct Professor of preclinical and early clinical development of biopharmaceuticals. In 2007 Miro moved to Novartis as Divisional Head in Biomarker Development, supervising a team of scientists developing assays and supporting project teams in the realization of personalized medicine strategies across the portfolio, with a focus on biologics and oncology programs. His team has contributed to the development of nilotinib (Tasigna) and early programs in both solid tumors and hematological malignancies. Since 2009, Miro joined Roche Oncology where he has contributed the biomarker and personalized medicine strategies and directed the execution for global drug development programs with companion diagnostics, including the development and approval of Perjeta in breast cancer. In 2011, he was appointed Site Head for Oncology Biomarkers within the DTA Oncology Dept, under the leadership of William Pao, and based in Penzberg, Germany. Miro has then been appointed Global Head of Diagnostics Biomarkers at Hoffmann-La Roche and is based at the Company’s headquarters in Basel.

Miro has contributed to several drug research and scientific development projects and published in a number of relevant scientific journals, including Nature, Cell, PNAS and others.
Novo Holdings A/S
Morten Døssing
Partner

Morten is a Partner at Novo Holdings, an evergreen fund with EUR 60 Bn under management. He works in Novo Seeds with a focus to identify, create, invest, manage (BoD level) and exit innovative biotech companies in Europe. Novo Seeds invests between 1-20 EURM per investment round and has a long term investment perspective.

Background in corporate development, M&A, business development, management consultancy, and technology transfer. In-depth transaction/negotiation/company creation expertise.

Deal sheet includes transactions with USD 2 Bn+ in total deal value and experience which spans pharma/biotech, medtech

Before coming to Novo, Morten was Director of Corporate Development/M&A at H. Lundbeck A/S a global specialty pharma company focusing on the area of CNS.

Earlier in his career, Morten co-led the life science consulting practice at a boutique advisory firm successfully building up the life science business.

Morten is a board member in NMD Pharma, Syndesi Therapeutics, CAMEL-IDS, Hoba Therapeutics and Avilex.

Pfizer, Inc.
Nathalie ter Wengel
European Head External R&D and Innovation

Nathalie ter Wengel, a medical doctor, is the European Head Global Scouting External Science and Innovation at Pfizer, where she is responsible for establishing new collaborations and exploring licensing and other corporate development opportunities across all therapeutic areas. She has an international background and a broad knowledge in the medical field, having worked in the hospital with extensive experience in internal medicine. Nathalie started her commercial career as European Medical Manager at Pfizer, where she successfully led ambitious international projects, combining a business perspective with her medical knowledge. It was this experience, coupled with her father’s illness, that convinced her of the urgent need for change in the pharmaceutical industry. Consequently, she started up a company called myTomorrows focused on compassionate use, and served as Chief Medical Officer before joining Galapagos as Business Development Director, where she played a key role in the very successful NASDAQ IPO and in partnering filgotinib.

Actelion, a Janssen Pharmaceuticals Company of Johnson & Johnson
Nicholas Franco
Executive Vice President & Chief Business Development Officer

Nicholas Franco has over 25 years of pharmaceutical leadership and experience in research, marketing, sales and business development across several therapeutic areas and geographies.

Prior to joining Actelion as Executive Vice President and Chief Business Development Officer, he was Senior Vice President, International Commercial Operations at Axcan Pharma based near Paris, France where he was responsible for ex-North American operations (including Marketing, Operations and Partnering).

Prior to that, he was Head of Market Access Region Europe for Novartis Pharma AG in Basel, Switzerland, where he has held various management positions since 1991, including President of Novartis Ophthalmics, Global Head, Business Development and Licensing Negotiations, Global Head, Neuroscience Franchise and Global Brand Director for gastrointestinal products.

Nicholas holds a BSc in Biochemistry and Masters in Business Administration, Strategic Planning and Marketing from McGill University (Canada).
Novartis International AG

Nigel Sheail
Global Head of M&A and BD&L

Nigel Sheail is Global Head of Mergers & Acquisitions and Business Development & Licensing since September 1, 2017 and joined Novartis in 2015 as Head of Business Development & Licensing. He is a member of the Financial Leadership Team.

Prior to joining Novartis, Nigel was Head of Business Development and Licensing for Bayer Healthcare. He also served as Head of Group M&A at Roche and Head of Licensing for their Pharma division.

Nigel has been responsible for a broad range of healthcare deals from research and technology collaborations through to large M&A transactions. Academically trained as a molecular biologist, Nigel is a qualified Chartered Accountant and has held a number of functions within the Pharmaceutical industry at Bayer, Roche and GSK.

In addition to his work in business development, Nigel has also worked as a global controller for research and was finance director responsible for the establishment of Roche’s operations in China which included five joint venture operating companies and a holding company. Nigel was the founding treasurer of the Swiss Pharma Licensing Group.

Nigel holds a Bachelor of Science degree in Molecular Biology with high honors from the University of Edinburgh, School of Biological Sciences and an ACA degree, ICAEW Chartered Accountant qualification.

ReNeuron Group Plc.

Olav Hellebo
CEO

Olav Hellebo was appointed as Chief Executive Officer in September 2014. A highly experienced, international pharmaceutical executive he has broad commercial experience gained at both major pharmaceutical and small biotechnology companies. He has particular experience of the clinical development, out-licensing, commercialisation and marketing of new therapeutics.

Prior to ReNeuron, Olav held the role of CEO at Clavis Pharma ASA, a Norwegian, oncology focused, listed biotechnology company. At Clavis, Olav built a multi-national leadership team, taking the company’s lead programme through Phase III clinical development as well as completing substantial fundraising and out-licensing transactions for the business. Prior to Clavis, Olav headed up the global biologics franchise at UCB Pharma and was head of the UK commercial operations of Novartis.

Olav started his pharmaceutical career in 1992 at Schering-Plough, where he held a number of senior commercial roles in Europe and the US, including leading its US commercial operations in the areas of oncology, cardiovascular and hepatitis-C, representing annual sales in excess of $2 billion. Olav has an MBA from the IESE Business School in Spain and a Bachelor of Business Administration from Hofstra University, USA.
Sanofi
Olivier Reinhard
VP, Head of Execution for China and Emerging Markets

Olivier Reinhard currently manages the portfolio of BD&L transactions for the Sanofi China and emerging markets GBU. He has an extensive experience in BD&L with over 15 years of experience working in transactions across multiple therapeutic areas and geographies. He joined Sanofi in 2001 where he held various business roles in Finance and Strategy & Business Development. Prior to Sanofi, Olivier started his career at UBS Investment Bank. Olivier holds a Master in Management from ESCP and an Applied Mathematics, Statistics and Computing degree from Paris IX Dauphine.

Janssen: Pharmaceutical Companies of Johnson & Johnson
Patrick Benz
Sr. Director Alliance Management

Patrick Benz, Senior Director Alliance Management, Janssen Business Development. In this role Patrick manages all global commercial and R&D key alliances for Neuroscience in all different global regions. Patrick joined Johnson & Johnson Family of Companies in 1998 at Janssen Switzerland. He progressed through several commercial roles into the board of the Swiss Operating Company as Business Unit Director CNS, and then moved to Italy, holding several commercial roles at board level, advancing to EMEA Franchise Leader for Neurology, overseeing the entire EMEA Neurology Franchise. Since October 2008, Patrick has been a member of the Janssen Business Development team. In this group he was holding the position of Senior Director, Business Development & Licensing for the Neuroscience Franchise until 2013, where he was negotiating several transactions for commercial as well as R&D assets. Patrick holds a Master Degree in Pharmacy and a PhD in Organic Chemistry. Before joining Janssen Switzerland in 1998, Patrick did work for Gebro Pharma AG, Switzerland, and for Boehringer Mannheim/Roche.

HealthCare Royalty Partners
Paul Hadden
Partner

Paul J. Hadden is a Partner and member of the Investment Committee at HCR. Mr. Hadden, based in London, is focused primarily on HCR’s activities in the United Kingdom and Europe, including transaction sourcing and structuring. Mr. Hadden previously led the firm’s global business development activities. Mr. Hadden has over a decade of healthcare investing experience in the royalty and debt markets, and has worked on investments representing over $950 million in transaction value. Prior to joining HCR in 2007 as HCR’s second employee, Mr. Hadden served as a principal at The Frankel Group LLC, a boutique management consulting firm serving the life sciences industry, where he advised pharmaceutical, biotechnology and generic clients. Mr. Hadden started his career at New York-Presbyterian Hospital as a senior financial analyst. Mr. Hadden holds a B.A. from Yale College and an M.P.H. from the Yale School of Public Health.

Bird & Bird LLP
Paul Hermant
Partner

Paul Hermant is a corporate & finance partner at Bird & Bird LLP, specialised in the life sciences sector and based in Brussels. He heads the firmwide corporate life sciences group. He assists clients in their corporate and financial transactions and provides the full range of advice in these fields. He has particular expertise in mergers and acquisitions, private equity, venture capital, joint ventures, strategic alliances, securities offerings, take-over bids, as well as project and acquisition finance. Paul also represents clients in corporate and financial litigation, including shareholders disputes, directors’ liability and cases relating to financial products and services. He graduated from the University of Brussels (Master in Law 1988, Master in Business Law 1989) and from the Solvay Business School (Master in Business Administration 1992). He joined Bird & Bird LLP in 2000, coming from Loeff Claeys Verbeke (now Allen & Overy). He has written and spoken widely on corporate and financial law topics and teaches at the University of Brussels. He also serves on the Board of the Solvay Business School Alumni.
12TH ANNUAL EUROPEAN LIFE SCIENCES CEO FORUM
FOR PARTNERING AND INVESTING IN BIOTECH & PHARMA INDUSTRY

Welcome

Crescendo Biologics Ltd.
Peter Pack
CEO

Peter Pack has 26 years of experience in the successful establishment and growth of international life science companies. For 18 years, he was CEO and Managing Director of product-oriented companies ranging from early stage up to international commercialization and profitability with several thousand certified products; predominantly working in Germany, the UK and Poland. He raised over $ 125 m in venture capital, worked on several Boards and headed companies with up to 400 employees.

He started his career in the initial team of MorphoSys AG (1993-1999) as co-inventor of the commercially most successful phage library and was co-founder and CEO of the cancer diagnostics company mtm laboratories (1999-2008). The companies for which Peter worked in central positions were either successfully sold (mtm laboratories, Polytech Ophthalmologie, Signature Diagnostics), highly profitable (LGC Standards, Polytech) and/or went public (MorphoSys AG).

Imcyse SA
Pierre Vandepapelière
CEO & CMO

Pierre Vandepapelière, M.D.,PhD is CEO and CMO of Imcyse since February 2015. Imcyse is a rapidly growing biotech company developing a technology platform offering multiples opportunities such as active specific immunotherapeutics (Imotopes) to treat and to prevent auto immune diseases or allergic diseases or to down regulation of immune response against immunogenic drugs. Before joining Imcyse he was head of early clinical research at GlaxoSmithKline Biologicals and has extended experience in development of prophylactic and therapeutic vaccines for infectious diseases worldwide. Pierre also spent 7 years in Paris as head of development of immunotherapeutics for auto immune diseases.

He graduated in Medicine at the Catholic University of Louvain, in Tropical Medicine at the Institute of Tropical Medicine in Antwerp, Belgium and has a PhD from the University of Gent.

Wellington Partners
Rainer Strohmenger
Managing Partner

With over 20 investments in start-up companies, Rainer is one of Europe’s most experienced venture capitalists in Life Sciences. Joining Wellington Partners in 1997, he became a Partner in December 2000. His more than 20 years of investment activity have involved financing of some of the most successful European biotech, medtech, diagnostics and healthcare IT companies.

In the late 1990s he co-managed Wellington’s investment in Swiss biotech player Actelion, which became the most successful venture-backed biopharmaceutical company in Europe and was acquired in 2017 by Johnson & Johnson for US$ 30 billion. He was also responsible for the investments in Grandis (acquired by Novartis), invendo medical (acquired by Ambu), NoemaLife (acquired by Dedalus), Wavelight (acquired by Alcon), Oxford Immunotec (NASDAQ: OXFD), Genkyotex (NYSE Euronext: GKTX), Definiens (acquired by Medimmune), immatics as well as mtm laboratories (acquired by Roche).

Prior to joining Wellington Partners, Rainer was involved in medical research with a primary focus on cardiovascular physiology and in research on health economics at the Ludwig-Maximilians-University in Munich, Germany.

Rainer holds a M.D. in medicine as well as a M.Sc. in economics, both from Ludwig-Maximilians-University in Munich, Germany, and was trained at the Entrepreneurship Center of the MIT, Boston, USA.

www.sachsforum.com
**Versant Ventures**  
**Roberto Iacone**  
VP, Entrepreneur In Residence

Roberto serves on the R&D leadership team at Ridgeline Therapeutics, Versant’s Basel based Discovery Engine and as EIR for the Versant Ventures Investment Team. He is responsible for sourcing and evaluating academic opportunities from European institutes, and for leading biology and translational activities for Ridgeline NewCos.

Roberto brings over 10 years of industry experience in preclinical research at Roche, having managed discovery programs across a range of therapeutic areas including Neuroscience, Immunology, Ophthalmology and Cardiometabolics. He most recently served as Roche’s Head of Rare Diseases Research, and established numerous external collaborations with academic and biotech partners. Roberto holds an M.D. from the University of Napoli, a Ph.D. from the Max Planck Research School for Molecular Cell Biology and Genetics, and did his post-doc research at NIBR in Basel.

**Oryzon Genomics S.A.**  
**Roger Bullock**  
Chief Medical Officer

Dr. Bullock is CMO of Oryzon Genomics, Spain. After 30 years of clinical trials and research he moved to the industry in 2017 to help deliver the first epigenetic programme in CNS disorders. He served in senior management positions in the UK NHS and has over 100 publications, as well as frequent international conference appearances.

**Camel-IDS NV**  
**Ruth Devenyns**  
CEO

Was Ogeda CFO up to the company’s acquisition by Astellas Pharma Inc. in May 2017. Previously worked in the financial industry for >20 years, both in healthcare investment banking (KBC Securities and Bank Degroof Petercam) as well as in healthcare venture capital (KBC Private Equity and Korys).
Lonza AG  
Sarah Holland  
Global Head of Licensing

Sarah Holland is Vice-President, BD&L Business Partner to Sanofi’s General Medicines and Emerging Markets business unit. Previously, Sarah was Head of External Science & Partnering, Europe at Sanofi. In this role she also oversaw the activities of teams located on US West Coast, and in China, Japan and Israel. She was responsible for cultivating relationships and bringing forward innovative external opportunities from key stakeholders located across the globe. Sarah joined Sanofi from Roche where she was the Life Cycle Leader for alectinib, an ALK inhibitor licensed from Chugai. The Life Cycle Team she led was responsible for all aspects of the program, including manufacturing, development, and submissions to FDA and EMA. Previously, Sarah was Global Head of Strategic Partnering at Roche in Switzerland and a member of the Partnering Leadership Team. Her team’s projects included pharma M&A transactions, including rapid company integrations, spin-outs and major strategic partnerships. Sarah championed Roche’s entry into rare diseases and re-entry into anti-bacterials. Prior to that, Sarah was the Global Head of CNS Partnering, responsible for all Partnering activities across neurology and psychiatry. Her first role at Roche was as Oncology Finder, when Sarah led the deal with Plexxikon that resulted in the launch of ‘Zelboraf’. Prior to Roche, Sarah was Global Brand Director at AstraZeneca during US and EU launch. This followed roles in strategic planning, pricing and health economics. Before AstraZeneca, she held local and international sales and marketing roles in diagnostics, biotech and pharmaceutical companies. Sarah gained her MBA from Manchester Business School, where she was a Visiting Fellow until 2004, and her D. Phil. and first degree at the University of Oxford.

Johnson & Johnson
Simon Blake  
Scientific Licensing, Immunology

Simon is the Scientific Licensing lead for the Immunology Therapeutic Area (ITA) at Janssen Research and Development. In this role he scouts, identifies and leads due diligence activities on assets of high strategic interest to the ITA. Simon joined J&J in 2004 as head of the Cardiovascular and Metabolic Diseases group within the Centocor organization. He then transitioned to a role in the Biopharmaceuticals group leading the external innovation efforts for that area prior to joining the BD team.

Simon has spent over 20 years in various roles in drug discovery and development mainly focused on the role of cytokines in connective tissue disorders. Simon holds a BSc (Hons) from Oxford Polytechnic, UK and obtained his PhD in Biochemistry while working at the Kennedy Inst. of Rheumatology in London, UK.

Metabomed Ltd.  
Simone Botti  
CEO

Dr. Botti has been Metabomed’s CEO since July 2016. Simone co-founded Metabomed while he was Head of the Israel Bioincubator Fund at Merck Ventures, which he joined in 2011. During his tenure at Merck Ventures Dr. Botti set up the Israel Bioincubator Fund, and established a number of early stage companies. Previously, he was Vice President, Business Development at RAD Biomed Accelerator, one of Israel’s leading Life science incubators. Prior to that, he was Senior Director of Business Development at Cogenics. He also served as a Board Member of IATI, the Israel Advanced Technology Industries association. Dr. Botti holds a PhD in Chemistry from the Weizmann Institute of Science, where he received the “Dov Elad” prize in Structural Biology and was NIH–ADDP Fellow at Northwestern University Medical School in Chicago.
Sofia Ioannidou
Director
Sofia joined Andera Partners (formerly Edmond de Rothschild Investment Partners) in 2009 and is a Director in the Life Sciences team. She currently sits on the board of Andera Portfolio companies LogicBio Therapeutics, Tricares, Sanifit and Avalyn. Previously, Sofia was an Associate Consultant with L.E.K. Consulting in London, and before that, she was a Research Scientist at Eyetech Pharmaceuticals, Inc, in Boston. Sofia completed undergraduate studies at the University of Oxford in Molecular and Cellular Biochemistry (2000) and obtained a PhD in Cell Biology from Cancer Research UK / UCL (2004).

Stephan Lensky is Chief Operating and Chief Business Officer of EpimAb Biotherapeutics GmbH, a company based in Shanghai, developing highly novel and proprietary bispecific antibodies, with its first candidate in Phase I trials in the US and China. He is responsible for the strategic, financing and BD efforts of EpimAb. Since its foundation Stephan raised over US$ 25 M in Series Seed and A of the company from Chinese, US and European investors to support EpimAb’s rapidly growing pipeline and is currently finalizing a Series B. Stephan brings over 20 years of experience in Pharma companies to EpimAb, e.g. as Corporate Vice President in Business Development at Boehringer Ingelheim, and holds a PhD in Chemistry.

Stéphane is CEO and co-founder of Gamamabs Pharma, a clinical-stage immuno-oncology biotech. Gamamabs developed a portfolio of innovative drugs in oncology whose lead compound, GM102, is a first-in-class immuno-enhancer drug in phase II. GamaMabs has also announced in November 2017 a collaboration and license agreement with Medimmune for the development of an ADC. Stéphane is a biotech entrepreneur and has a finance background. Graduated from ESCP Europe (majoring in Finance), he started his career at Sanofi in Finance and was co-founder of Endotis Pharma, a biotechnology company in cancer and thrombosis.

Stephanie Léouzon is Partner and Head of Europe for Torreya Partners, a life sciences boutique advisory firm which she joined in 2012. Previously she worked in healthcare investment banking in the US and Europe from 1989 to 2010, most recently at Credit Suisse in London as a Managing Director and Senior Advisor.She has advised life sciences clients on more than 25 strategic transactions, valued at over $65 billion, and has been involved in over 45 financing transactions to provide over $10 billion to healthcare clients. Stephanie earned an MBA degree from the Darden Graduate School of Business at the University of Virginia in 1989 and a BA degree, cum laude, from Mount Holyoke College in 1985.
MorphoSys AG

Susanne Wiegel

Senior Director, Deputy Head BD

Susanne has worked over 10 years at MorphoSys focusing on business development and portfolio management. She has negotiated a multitude of deals, focusing on inlicensing and outlicensing of clinical stage candidates with leading pharma and biotech companies worldwide, securing 100 million Euro in revenue for the company plus hundreds of millions of upside in milestones and royalties, and inlicensing its most transformative asset. Previously, she worked in strategy consulting with McKinsey&Co advising pharma, healthcare and specialty chemicals, and in business development for biotech company Medigene.

Susanne received her PhD in biochemistry from University of Braunschweig, and performed the PhD thesis at Helmholtz Institute for Infectious Diseases in Braunschweig, Germany.

Eli Lilly and Company

Timothy Luker

VP, Emerging Technology & Innovation, BD

Tim Luker leads Lilly’s external advancing innovation process in Europe within Global Corporate Business Development. In this role Tim interacts with numerous external VC funds targeting transformational early stage research across multiple therapy areas and also supports general due diligence and search and evaluation initiatives. He also chairs the internal Lilly venture fund deal flow triage team which ensures the most exciting external science is prioritised.

Tim is an experienced drug hunter with 18 years’ experience and is an inventor / author on >60 patent applications and publications. Prior to Lilly he co-founded a successful spin out biotech (Polleo Pharma, acquired 2016); and performed senior roles at Shire pharmaceuticals (Director Exploratory projects, 2011-2014) and AstraZeneca (several R&D and medicinal chemistry roles, 1999-2011), where he led multiple drug discovery projects through to candidate molecules as well as providing input into early development projects and managing medicinal & computational chemistry teams. Many of these projects reached efficacy studies in human.

Tim has a PhD (1995) in chemistry from the University of Southampton, carried out post-doctoral research at Universiteit Van Amsterdam (1996-1999) and is also a Prince2 qualified project manager.
Gadeta B.V.
**Tolleiv Trimborn**
COO

Dr. Tol Trimborn (co-founder) has over 20 years of experience in the life sciences and venture capital industry. He is a highly motivated, creative and dynamic entrepreneur. Tol has co-founded several companies including DNage (acquired by Pharming), Arcarios, and Gadeta (collaboration with Kite-Gilead), and served in a variety of management capacities. He started his career as Postdoctoral fellow at Stanford, lead molecular biology group at Kalobios, and developed his commercially oriented network at investment firm LSP. Tol holds a PhD in Medical Biology from the Erasmus University Rotterdam, and Masters degrees in Biology and Chemistry from Leiden University, The Netherlands.

Inthera Bioscience AG
**Ulrich Kessler**
CEO

Ulrich Kessler has more than 15 years of experience in life science R&D, drug discovery and pharma business development in the US and Switzerland. Since 2013 he is the CEO of Inthera Bioscience, for which he raised more than USD 15 million. Inthera is developing small molecule transcription modulators that reprogram cancer cells. Before, Ulrich worked for F. Hoffmann La Roche AG’s oncology franchise as International Product/Business Manager and the healthcare franchise of the Boston Consulting Group, advising large pharma customers on R&D operations and product launch strategies. Ulrich holds a MSc in pharmaceutical sciences, a PhD in applied biosciences from ETH Zurich and completed a postdoctoral fellowship at the Institute of Chemistry and Cell Biology at Harvard Medical School, focusing on chemical genetics approaches and identification of novel cell cycle inhibitors.

Abingworth LLP
**Vanessa King**
Venture Partner

A geneticist by training, Dr. Vanessa King has spent the last two decades pursuing her passion for turning innovative science into effective treatments.

Building on her expertise as a serial entrepreneur, she currently serves as a Venture Partner at Abingworth LLP. Dr. King is also CEO of Virion Biotherapeutics, a company focused on transforming how respiratory virus infections are treated. Virion is developing a first-in-class RNA immunomodulatory agent to deliver broad spectrum antiviral activity, addressing the fourth biggest killer globally.

Prior to Virion, Dr. King was CEO of Luc Therapeutics, focused on modulating the brain’s synaptic plasticity. Before that, Vanessa led business development in the turnaround team for deCODE Genetics, taking the company from bankruptcy to a $415M acquisition by Amgen.

Dr. King’s other roles have spanned business development, strategy and operations at Novartis, Amgen, and the J. Craig Venter Institute. She obtained her Ph.D. in Molecular Genetics from Trinity College, Cambridge, UK and her AB Phi Beta Kappa in Molecular Biology from Princeton University.
**MetrioPharm AG**  
**Wolfgang Brysch**  
Founder & CEO

- Co-founder, multiple entrepreneur, physician
- Senior positions at the Max Planck Institute, Biognostik, Antisense Pharma, BioMedion, Athenion
- Many years of experience as Chief Scientific Officer, primarily in drug development

Dr. Wolfgang Brysch has been Chief Executive Officer of MetrioPharm AG since 2016, before which he was Chairman of the Board of Directors and Chief Scientific Officer (2007-2016). In 2001, he co-founded BioMedion – a successful IT company specializing in solutions for the pharmaceutical industry. He was Managing Director there until 2007. Prior to that, he worked at Biognostik GmbH, where he was Managing Director and Chief Scientific Officer (CSO) from 1992 to 2001. At that time, Dr. Brysch was also responsible for the preclinical development of various antisense cancer drugs at Antisense Pharma. Until 1992, Dr. Brysch was head of a research group for molecular neurobiology and cancer research at the Max Planck Institute for Biophysical Chemistry in Göttingen, Germany.

**Anima Biotech, Inc.**  
**Yochi Slonim**  
Co-Founder & CEO

Yochi Slonim is a serial entrepreneur with a track record of over 30 years in software and biotech.

As a Co-founder and CEO, he is driving the company’s vision and strategy, fundraising, and partnering.

Prior to Anima, Yochi has built several companies from their early stage, through all stages of product development, marketing, and sales and eventually turned them into successful large exits.

He was a co-founder of Mercury Interactive. As CTO and VP R&D from the company’s early days, he created product vision and strategy and led a multi-product organization of 200 developers. After going public and reaching revenues of over $1B annually, Mercury was acquired by HP for $4.5B.

As Senior VP of products and marketing for Tecnomatix, a public NASDAQ company, he led a 500 people organization of 4 divisions that generated revenues of $100m until the company was acquired by UGS for $230m.

In 2000, Yochi was founder and CEO of Identify. The company reached revenues of $50m in less than 5 years and was acquired by BMC in 2006 for $150m in cash.

Yochi founded ffwd.me, a unique startup acceleration program where he led a team that worked with over 25 startups in diverse areas and technologies, developing strategy, products and go to market operations while raising multiple rounds of financing from VCs and private investors.

As one of Israel’s leading speakers on the subject of startup positioning and company building, several of Yochi’s approachable and amusing lectures can be found on Youtube ("Youtube Yochi Slonim").
ABIVAX

COMPANY PROFILE

As a clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to optimize and develop drug candidates to treat ulcerative colitis and other inflammatory diseases (ABX464), HIV (ABX464), and liver cancer (ABX196). Our mission is to utilize Abivax’s drug development platforms to bring innovative and effective solutions to patients in these therapeutic areas with significant unmet needs.

MANAGEMENT TEAM

- Prof. Hartmut J. Ehrlich, M.D. - Chief Executive Officer
- Didier Blondel - Chief Financial Officer & Board Secretary
- Jean-Marc Steens, M.D. - Chief Medical Officer
- Pierre Courtelle, Pharmacist, MBA - Chief Commercial Officer & Vice President of Business Development
- Jérôme Denis, Ph.D. - Vice President Process Development & Manufacturing
- Alexandra Pearce, Ph.D. - Vice President of Regulatory Affairs, Quality and Pharmacovigilance
- Didier Scherrer, Ph.D. - Vice President of R&D
- Paul Gineste, Pharm D. - Vice President of Clinical Operations
- Prof. Jamal Tazi, Ph.D – Vice President Research and Scientific Director of the Abivax – CNRS Collaborative Laboratory

PIPELINE

Inflammation

- Ulcerative Colitis
  - Anti-inflammatory
  - ABX464 Phase 2a complete Phase 2a in preparation

- Crohn’s Disease
  - Anti-inflammatory
  - ABX464 Phase 2a in preparation

- Rheumatoid Arthritis
  - Anti-inflammatory
  - ABX464 Phase 2a in preparation

Antiviral

- HIV
  - Lasting viral remission
  - ABX454 Phase 2a complete Phase 2a in preparation

- Ebola
  - Polyclonal antibodies
  - ABX544

- Respiratory Syncytial Virus
  - Antiviral drug

- Dengue
  - Antiviral drug

- Influenza
  - Antiviral drug

Cancer

- Hepatocellular Cancer
  - Immune Enhancer
  - ABX196 in Phase 12 POC clinical trial in POC to start H1 2019
Allecra Therapeutics GmbH

COMPANY PROFILE

Allecra’s mission is to contribute to the global effort to combat anti-biotic resistance. Antibiotic resistance is widespread and growing exponentially. Allecra’s contribution is to develop new treatments which overcome emerging resistance mechanisms, thereby saving lives of patients whose infections will otherwise be inadequately treated.

Allecra has a novel β-lactamase inhibitor administered in a fixed dose combination with cefepime as IV infusion in Phase 3 clinical development. The product is designed to overcome resistance of Gram-negative hospital pathogens harboring extended spectrum β-lactamases (ESBLs) and has demonstrated to have a carbapenem-sparing activity. Ph 3 results in Complicated Urinary Tract Infections (cUTI) as lead indication are expected in Q4 2019. The program has been developed as the new empirical therapy for serious hospital infections where ESBLs are suspected, replacing current standard of care.

Allecra Therapeutics is situated in the BioValley Life Sciences region in the Upper Rhein valley which encompasses northwest Switzerland, southwestern Germany and the Alsace region of France.

MANAGEMENT TEAM

- Klaus Wilgenbus - Chief Executive Officer and Managing Director
- Mathias Knecht - Chief Development Officer and Managing Director
- Andrew Smith - Chief Financial Officer
- Huw Tippett - Chief Commercial Officer
- Björn Peters - Head of Business Development

PIPELINE

Cefepime/Enmetazobactam – a novel proprietary carbapenem-sparing BL/BLI combination in Ph 3 for the treatment of MDR gram-negative hospital acquired infections, esp. ESBL resistance
AMYRA Biotech AG

COMPANY PROFILE

AMYRA is developing therapeutic product applications for the treatment of celiac disease and gluten sensitivity, which represent major public health issues.

The global prevalence is 1-3% for celiac disease and 6-10% for gluten sensitivity, resulting in huge markets, estimated at USD 8 bn and USD 15 bn, respectively, which are basically untapped.

Both conditions are triggered by the ingestion of gluten, which is ubiquitously present in the Western diet and thus almost impossible to avoid.

MANAGEMENT TEAM

- Dr. Werner Tschollar - Founder, CEO and Chairman of the Board of Directors
- Caspar Graf Von Moy - Founder, COO and member of the Board of Directors
- Priv. Doz. Dr. Ghazaleh Gouya, CMO
- Patrick Schacher - CFO

PIPELINE

AMYRA’s two lead product candidates are AMY01 for the treatment of celiac disease and AMY02 for the treatment of gluten sensitivity. Each product comprises of two proprietary, synergistically acting, recombinant enzymes that rapidly (within a few minutes) and entirely destroy the immunogenic structure of toxic gluten fragments (gliadins) – a phenomenon that has never been shown before. The enzymes are safe, highly effective, stable and resistant to endogenous enzymes. The Proof-of-concept in gastrointestinal models has been successfully completed and showed no local or systemic toxicological reactions. The Upstream-and downstream process, cell banking and analytical method development has been finalized in collaboration with LONZA AG. Also, the tech transfer (Scale-up to 1'000 L bioreactor volume) and the formulation development is concluded. AMYRA is now in the process of preparing the in-vivo study in humans (substance-based medical device class III).
Anagenesis Biotechnologies

COMPANY PROFILE

Anagenesis Biotechnologies is a preclinical-stage stem cell-based company focused on developing novel treatments for muscle degenerative diseases and type 2 diabetes. Anagenesis Biotechnologies secured private investments from the AFM (French muscular dystrophy association) to develop applications in the skeletal muscle therapeutic area, from Cap Innov’Est and form the Boehringer Ingelheim Venture Fund. Anagenesis Biotechnologies aims to complete now a series A funding of at least 15 M€ under the lead of the Boehringer Ingelheim Venture Fund.

MANAGEMENT TEAM

- Jean-Yves Bonnefoy, PhD - President & CEO, Co-founder & Board member
- Mélissa Guyot - Operating officer
- Aurore Hick - Lab Head
Anima Biotech, Inc.

COMPANY PROFILE

Anima Biotech is advancing Translation Control Therapeutics, the first and only platform for the discovery of small molecule drugs that specifically control mRNA translation as a new strategy against hard and undruggable targets in many diseases.

Anima’s proprietary technology enables visualization and monitoring of target protein translation via pulses of light emitted by ribosomes. The fully automated high-throughput screening system discovers small molecules that modulate the light, as they decrease or increase the target protein's production. The platform integrates proprietary technologies in biology, bioinformatics, image analysis, big data analysis and artificial intelligence algorithms in a cloud computing software architecture.

Anima is developing an internal pipeline across multiple therapeutic areas with high unmet need and hard targets. Current programs are in Fibrosis (inhibiting the synthesis of Collagen type I), Viral infections (Respiratory Syncytial Virus – interfering with viral protein synthesis), Oncology (C-Myc translation inhibitors) and Huntington’s disease (monitoring mutant Huntingtin translation pausing).

Anima’s Translation Control Therapeutics platform is strategically designed for partnering with Pharma. The power of Anima’s approach was solidified with a $1B+ collaboration with Lilly for the discovery and development of translation inhibitors of several targets. Anima's technology has been further validated by 5 granted patents, 14 peer reviewed publications and 17 scientific collaborations.

MANAGEMENT TEAM

- Yochi Slonim (Co-founder & CEO)
- Zeev Smilansky (Co-founder & CSO)
- Avi Eliassaf (COO)
- Iris Alroy (VP R&D)
- Kevin Pong (VP Business Development)
- Dave Sheppard (Head Of Chemistry)
- Yossi Oulu (VP Digital Technologies)

PIPELINE

Our pipeline programs are in Fibrosis (Collagen type I translation inhibitors), RSV (inhibiting the production of viral proteins by host cell ribosomes), Oncology (C-Myc translation inhibitors) and Huntington’s Disease (monitoring mutant Huntingtin translation pausing).

<table>
<thead>
<tr>
<th>PROGRAM</th>
<th>ASSAY DEVELOPMENT</th>
<th>HIT GENERATION</th>
<th>HIT TO LEAD</th>
<th>PRECLINICAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Collagen I – Target 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lung Fibrosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Collagen I – Target 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver Fibrosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Collagen I – Target 3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Extremities</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RSV</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Viral Translation Inhibitors</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C-Myc</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oncology / Longevity</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Huntington’s disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Artidis AG

COMPANY PROFILE

At ARTIDIS AG, we are committed to radically improving health outcomes by harnessing the power of nanotechnology and innovation. ARTIDIS™, our innovative new nanomechanical biomarker tool for cancer diagnosis and treatment, seeks to improve people's lives by dramatically reducing the time it takes to accurately diagnose breast cancer—from a period of days or weeks to as little as three hours—thereby substantially reducing anxiety and time lost. ARTIDIS™ will also improve lives by facilitating personalized treatments, based on precise nanopalpation measurements of cancer aggressiveness and correlation to individuals' specific medical data and histories.

We believe that same-day diagnosis and individually-based treatment are the future in the era of value based health care. We also believe that medicine should be informed by the very latest discoveries in cutting-edge research. Accordingly, we are working on applications for our technology to the treatment of diseases beyond breast cancer. At ARTIDIS AG, we are committed to innovation and excellence, in order to bring the future of health care to people today.

MANAGEMENT TEAM

- Dr. Marija Plodinec - Board Member & CEO
- Dr. Marko Loparic - CMO
- Dr. Philipp Oertle - Chief Scientific & Development Officer
- Tobias Appenzeller - Head of Quality & Clinical Operations
ATRIVA Therapeutics GmbH

COMPANY PROFILE

Atriva Therapeutics is a leader in novel antiviral therapies of severe respiratory diseases, such as influenza, hanta, corona and RSV. Atriva is a pioneer targeting host-cell factors instead of viral factors. The lead compound ATR-002, a novel MEK inhibitor has entered clinical development in Q1 2019. The key USPs of ATR-002 against all competitors are:

- Targeted action of the drug since the pathway is only active in infected cells.
- Broad activity against circulating and newly emerging RNA viruses.
- Prolonged therapeutic activity infection even after several days post infection.
- Risk of resistance is negligible since the virus cannot replace the missing cellular function.
- Significant activity against Influenza-like-Illness (ILI).

Next major milestone will be end of Phase 2 PoC: in late 2020, a major value inflection. The company has received $6Mn capital up to now. The Series A 1 is ramping-up, with a first closing in January 2019, and a total of €16 Mn sought to drive the company to the first value inflection in late 2020.

MANAGEMENT TEAM

- Rainer Lichtenberger, Ph.D., MBA - President and CEO
- Prof. Oliver Planz, Ph.D. - CSO
- Christian Wallasch, Ph.D. - COO
- Sebastian Canisius, MD, Ph.D. - CMO
- Hendrik Lueßen, Ph.D. - CBO

PIPELINE

ATR-002: Highly specific MEK-inhibitor. Indication influenza in high-risk patients, clinical stage Q1 2019

ATR-004: MEK-inhibitor. Indication Hantavirus, preclinical stage, Orphan Designation in Q1 2019

ATR-006: RSV in COPD exacerbations, MEK-inhibitor, preclinical stage, clinical stage in Q3 2021
BAYOOMED Medical Software

COMPANY PROFILE

BAYOOMED is specialized in the development of medical apps and medical software. With more than 250 person years of project experience, BAYOOMED is highly professional in the regulated CE & FDA environment. We support more than 800 medical and pharma companies and are among the most experienced medical software developers in Europe.

We engineer MHEALTH / EHEALTH applications under iOS (iPhone & iPAD) and Android according to IEC 62304 and support product developers and innovators from the pharmaceutical and medical technology sectors in all phases of software product lifecycle. Our Quality management processes certified by TÜV Hessen according to ISO 13485 are a testament to our passion for sustainable solutions and distinct customer focus.

MANAGEMENT TEAM

• Stefan Becher - Chief Executive Officer
• Frank Manger - Chief Executive Officer
**BioInvent International AB**

**COMPANY PROFILE**

Based on its insights in immunology, cancer biology and antibody biology, BioInvent aims to develop cancer immunotherapies to improve the quality of life for cancer patients.

BioInvent’s current operational activities are focused on:

- Progressing and expanding the clinical development of its lead antibody BI-1206 for treatment of haematological cancers.
- Developing pre-clinical first-in-class antibodies targeting tumour-associated myeloid cells in collaboration with Pfizer.
- Advancing three compounds into clinical programs in solid cancer: anti FcγRIIB antibody in combination with anti-PD1 antibody - projected start phase I/IIa in H1 2019; BI-1607 (an anti FcγRIIB antibody) in combination with check point inhibitor - projected start phase I proof of concept trial in H2 2019; BI-1808 (anti-“EmergingTNFRS” antibody), as single agent and in combination with anti-PD1 antibody – projected start phase I in H1 2020.
- Advancing its pre-clinical Treg immuno-oncology programmes identifying antibodies to novel targets and pathways, as well as differentiated antibodies with new mechanisms-of-action to validated targets.
- Intensify the collaboration with Transgene to start the development of oncolytic virus (OV) candidates encoding a validated anti-CTLA-4.

**MANAGEMENT TEAM**

- Martin Welschof - Chief Executive Officer
- Björn Frendéus - Chief Scientific Officer
- Stefan Ericsson - Chief Financial Officer
- Andres McAllister - Chief Medical Officer
- Kristoffer Rudenholm Hansson - Senior Vice President, Technical Operations

**PIPELINE**

<table>
<thead>
<tr>
<th>Indication</th>
<th>Target</th>
<th>Program</th>
<th>Discovery</th>
<th>Preclinical</th>
<th>Phase I</th>
<th>Phase II</th>
</tr>
</thead>
<tbody>
<tr>
<td>NHL (MCL, MZL, IFI)</td>
<td>FcγRIIB</td>
<td>BI-1206 / rituximab</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>solid cancer</td>
<td>FcγRIIB</td>
<td>αFcγRIIB</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>solid cancer</td>
<td></td>
<td>BI-1607</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>solid cancer</td>
<td>Tregs</td>
<td>αCTLA-4 GM-CSF-IV</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>solid cancer</td>
<td></td>
<td>αTNFRS (Emerging)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>solid cancer</td>
<td></td>
<td>F.I.R.S.T™ αTreg</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>solid cancer</td>
<td></td>
<td>F.I.R.S.T™ αTAMs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* BioInvent additionally has ownership in anti-PDG programs TD-403 and THR-317 partnered with Oncurie and Oxurion
* Two parallel Clinical Phase I/II studies ongoing with BI-1206 (BioInvent and CRUK co-owned)
BioVersys AG

COMPANY PROFILE

BioVersys AG is a privately owned Swiss pharmaceutical company focusing on research and development of small molecules acting on novel bacterial targets with applications in Anti-Microbial Resistance (AMR) and targeted microbiome modulation. With the company’s award-winning TRIC technology we can overcome resistance mechanisms, block virulence production and directly affect the pathogenesis of harmful bacteria, towards the identification of new treatment options in the antimicrobial and microbiome fields. By this means BioVersys addresses the high unmet medical need for new treatments against life threatening resistant bacterial infections and bacteria-exacerbation chronic inflammatory microbiome disorders. Our most advanced R&D programs are in preclinical development for nosocomial infections (hospital infections), and Tuberculosis in collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille. In 2019 BioVersys plans to launch our first Phase I clinical trials and transition into a clinical stage company. BioVersys is located on the Technologiepark in the thriving biotech hub of Basel.

MANAGEMENT TEAM

- Dr. Marc Gitzinger - CEO and Co-Founder
- Dr. Sergio Locciuro - Chief Scientific Officer
- Dr. Glenn Dale – Chief Development Officer
- Dr. Jonathan J. Butcher - Head Business Development & Alliance Management
- Matthias Werder - Chief Financial Officer

PIPELINE

BioVersys will start two Phase I clinical programs in 2020 and relies on a highly diverse pipeline addressing the highest unmet medical need indications around the current antimicrobial resistance crisis. The pipeline is highly de-risked and offers a unique investment opportunity benefitting from the changing re-imbursement and regulatory environment for novel antimicrobials, only to the escalating costs of healthcare but also cause high numbers of casualties worldwide.
Boston Pharmaceuticals, Inc.

COMPANY PROFILE

Boston Pharma is a translational drug development company. It was founded in 2016 by Chris Viehbacher, ex-CEO of Sanofi and Rob Armstrong, ex-R&D Executive from Eli Lilly. With $600M committed capital from Gurnet Point Capital, Boston Pharma’s business model is focused on partnering and developing therapeutics from late pre-clinical to clinical POC. In the past 2 years, we have built an experienced clinical development team and acquired a diverse portfolio of seven programs in oncology, autoimmune, cardiovascular and antibiotics from Pharma and biotech partners. In principle, we are agnostic with regards to indication or molecular modality. We are looking forward to discussing any potential collaboration opportunities with you.

MANAGEMENT TEAM

- Robert Armstrong, PhD - Chief Executive Officer & Co-Founder
- Peter Ho, MD, PhD - Chief Medical Officer
- Constantine Chinoporos - Chief Business Officer
- Ian Sanderson - Chief Financial Officer

PIPELINE

Phase 2

Anti-Infective
- BOS-228 MonB
- BOS-161721 Anti-IL-21 LUPUS
- BOS-589 RETI IRS-D

Auto-immune

Gastrointestinal

Phase 1

Auto-Immune
- BOS-172767 ROR-yb
- BOS-173717 S1P1
- BOS-475 BETI
- BOS-356 DGAT1
- BOS-172722 MPS-II
- BOS-172738 RETI

Auto-Immune

Dermaology

Pre-Clinical

Anti-Infective
- BOS-572 BLi
- BOS-181 LpxCi

Cardiology
- BOS-1728515 ICI

Metabolic
- BOS-704

Undisclosed
- BOS-981
- BOS-857
Brainstorm Cell Therapeutics, Inc.

COMPANY PROFILE

BrainStorm Cell Therapeutics (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as:

- Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease and Motor Neuron Disease)
- Multiple Sclerosis
- Parkinson's Disease
- Huntington's Disease

Our platform technology, NurOwn®, uses proprietary culture conditions to induce mesenchymal stem cells (MSCs) to secrete high levels of neurotrophic factors (NTFs) known to promote the survival of neurons. Our research efforts have shown that these MSC-NTF cells might be an effective tool for battling neurodegenerative diseases.

MANAGEMENT TEAM

- Chaim Lebovits - President and Chief Executive Officer
- Ralph Kern, M.D., MHSc - Chief Operating Officer and Chief Medical Officer
- Arturo Araya - Chief Commercial Officer
- Joseph Petroziello, BSc, MSc - VP of Scientific and Corporate Communications
- Susan E. Ward, Ph.D. - Head of Clinical Operations
- Eyal Rubin - EVP, Chief Financial Officer
- Uri Yablonka - EVP, Chief Business Officer
- Mary Kay Turner - VP of Patient Advocacy and Government Affairs
- Yael Gothelf, Ph.D. - VP Scientific and Regulatory Affairs
- Yossef Levy, Ph.D. - VP Cell Production
- Alex Burshtein, M.Sc. - Quality Assurance Manager
- Revital Aricha, Ph.D. - VP Research & Development

PIPELINE

ALS- Amyotrophic Lateral Sclerosis (Lou Gehrig's disease)

<table>
<thead>
<tr>
<th>PRECLINICAL</th>
<th>PHASE 1</th>
<th>PHASE 2</th>
<th>PHASE 3</th>
</tr>
</thead>
</table>

Progressive MS- Multiple Sclerosis

<table>
<thead>
<tr>
<th>PRECLINICAL</th>
<th>PHASE 1</th>
<th>PHASE 2</th>
<th>PHASE 3</th>
</tr>
</thead>
</table>

Autism

<table>
<thead>
<tr>
<th>PRECLINICAL</th>
<th>PHASE 1</th>
<th>PHASE 2</th>
<th>PHASE 3</th>
</tr>
</thead>
</table>
Cue Biopharma, Inc.

COMPANY PROFILE

Cue Biopharma is dedicated to developing a robust pipeline of novel immuno-therapies focused on oncology, autoimmunity and chronic infections. We are building upon fundamental immunological principles to directly engage the immune system with an unprecedented level of specificity and sophistication. Our Immuno-STAT (Selective Targeting and Alteration of T cells) Biologics platform is designed to directly engage with and modulate the activity of antigen-specific T cells in the patient’s body, offering the potential for enhanced efficacy with minimal toxicity.

MANAGEMENT TEAM

• Dan Passeri, M.Sc., J.D. - President and Chief Executive Officer
• Anish Suri Ph.D. - Chief Scientific Officer
• Bethany Mancilla - Senior Vice President and Chief Business Officer
• Kenneth Pienta, M.D. - Acting Chief Medical Officer
• Colin Sandercock, M.Sc., J.D. - Senior Vice President and General Counsel
• Kerri-Ann Millar - Vice President of Finance and Principal Accounting and Finance Officer

PIPELINE

Cue Biopharma is working at the cutting edge of the immunotherapy revolution, with the potential to offer patients significant therapeutic advantages while minimizing or eliminating unwanted side effects. Our goal is to develop and bring to market biologics that can overcome the challenges faced by prevailing immuno-therapeutics, via direct engagement with and modulation of disease-associated T cells in a patient’s body.
Emerald Health Pharmaceuticals, Inc.

COMPANY PROFILE

Headquartered in San Diego, California & Córdoba, Spain, Emerald Health Pharmaceuticals (“EHP”), is a clinical-stage drug development company focused on treating life-threatening diseases through cannabinoid science. The company has two families of patented new chemical entities (“NCEs”), which are derivatives of cannabidiol (“CBD”) and cannabigerol (“CBG”) that it has modified through rational drug design to affect validated receptors and pathways pertinent to targeted diseases. Its first drug candidate, EHP-101, is focused on treating multiple sclerosis and scleroderma, which is in Phase I clinical development. Its second, EHP-102, is focused on treating Huntington’s disease and Parkinson’s disease, in preclinical development.

MANAGEMENT TEAM

- Avtar Dhillon, MD - President & Executive Chairman
- Jim DeMesa, MD, MBA - CEO
- Lisa Sanford - Interim Chief Financial Officer
- Alain Rolland, PharmD, PhD - Executive VP & CDO
- Joachim P.H. Schupp, MD, Dr. med. - Chief Medical Officer
- Nancy Coulson, MBA - VP, Regulatory and Quality Affairs
- Eduardo Muñoz, PhD, MD - Chief Scientific Officer
- Giovanni Appendino, PhD - Scientific Advisor

PIPELINE

<table>
<thead>
<tr>
<th>Product Candidate</th>
<th>Indication</th>
<th>Proof-of-concept</th>
<th>Formulation</th>
<th>Preclinical</th>
<th>Phase I</th>
</tr>
</thead>
<tbody>
<tr>
<td>EHP-101</td>
<td>Multiple sclerosis</td>
<td>Orphan designation granted, US and EU</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Scleroderma</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EHP-102</td>
<td>Parkinson’s disease</td>
<td>Orphan designation granted, US</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Huntington’s disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
EpimAb Biotherapeutics GmbH

COMPANY PROFILE

EpimAb Biotherapeutics is a privately owned biopharmaceutical R&D company based in Shanghai with a proprietary, unique and efficient technology called FIT-Ig® (Fabs-In-Tandem Immunoglobulin) that generates bispecific molecules with antibody-like properties. With this innovative platform, EpimAb is creating a potentially game-changing pipeline of its own novel bispecific antibody therapeutics focused around immuno-oncology and other areas of high value to patients.

MANAGEMENT TEAM

- Chengbin Wu, Ph.D - CEO
- Dr. Stephan Lensky - CBO/COO
- Bin Peng, MD, Ph.D - CMO
- Richard Jiang - VP Regulatory Affairs
- Jason Li, Ph.D - VP CMC Development

PIPELINE

**EMB-01** is a bispecific antibody based on EpimAb’s proprietary platform FIT-Ig® that has shown efficacy in multiple preclinical cancer models. It targets the Epidermal Growth Factor Receptor (EGFR) as well as the Hepatocyte Growth Factor Receptor (cMET) with a clearly differentiated mechanism of action from currently available EGFR and cMet therapies. EMB-01 is in being investigated in a Phase I/II in the US and China for treatment of solid tumors.

Further candidates:

EpimAb’s next candidate **EMB02**, a bispecific inhibitor of PD1 and LAG3, is currently in preclinical development.
Exicure, Inc.

COMPANY PROFILE

Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary spherical nucleic acid (SNA™) architecture is designed to unlock the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address inflammatory diseases, genetic disorders and oncology. Exicure is based outside of Chicago, IL.

SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.

SNA™ technology originated in the lab of Professor Chad A. Mirkin at the Northwestern University International Institute for Nanotechnology. Exicure’s intellectual property portfolio includes over 135 pending patent applications and over 60 allowed or issued patents. These filings impact numerous jurisdictions worldwide, and they cover a range of inventions, including fundamental nanoparticle manufacturing breakthroughs and numerous application-specific improvements.

MANAGEMENT TEAM

• David A. Giljohann - Chief Executive Officer
• David Snyder - Chief Financial Officer
• Ekambar Kandimalla - Chief Scientific Officer
• Matthias Schroff - Chief Operating Officer
• Jocelyn Trokenheim - Vice President, Head of Business Development

PIPELINE

Exicure has a broad pipeline of SNA-based therapeutics to treat a range of diseases with great unmet medical need. The unique properties of the SNA constructs allow the use of oligonucleotide-based therapies to treat diseases in a range of tissue types.

<table>
<thead>
<tr>
<th>Therapeutic Area</th>
<th>Therapeutic Candidate/Target</th>
<th>Indication</th>
<th>Development Stage</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immuno-oncology</td>
<td>AST-008 (TLR9 agonist)</td>
<td>Solid Tumors</td>
<td>Research Preclinical Development, Phase 1</td>
<td>Phase 1 data reported Q3 2016 (1) Preliminary results in 2016 (1)</td>
</tr>
<tr>
<td>Dermatology</td>
<td>XCUR17 (AQP1-L/I1MA)</td>
<td>Pemphigus (2)</td>
<td>Phase 1 topline results announced late 2018 (3)</td>
<td></td>
</tr>
<tr>
<td>Neurology</td>
<td>SNM2</td>
<td>Spinal Muscular Atrophy</td>
<td>Superior potency improves survival and safety compared to musin in vivo</td>
<td></td>
</tr>
<tr>
<td>Neurology</td>
<td>HTT</td>
<td>Huntington’s Disease</td>
<td>Target knockdown in vivo</td>
<td></td>
</tr>
<tr>
<td>Ophthalmology</td>
<td>Undisclosed</td>
<td>Undisclosed</td>
<td>Delivery to retina in vivo</td>
<td></td>
</tr>
<tr>
<td>Gastro-oncology</td>
<td>Undisclosed</td>
<td>Inflammatory Bowel Disease</td>
<td>Target knockdown in tissue Activity in mouse model of IBD</td>
<td></td>
</tr>
<tr>
<td>Pulmonology</td>
<td>Undisclosed</td>
<td>Undisclosed</td>
<td>Delivery via aerosol Activity in mouse model</td>
<td></td>
</tr>
<tr>
<td>Partnered Program</td>
<td>Dermatology AST-305</td>
<td>TBI</td>
<td>Research Preclinical Development, Phase 1</td>
<td>Phase 1 complete</td>
</tr>
</tbody>
</table>

(1) In combination with checkpoint inhibitors (2) Mild to moderate (3) In collaboration with Purdue Pharma
Forendo Pharma Ltd.

COMPANY PROFILE

Forendo Pharma is a clinical stage drug development company, with core competences in modulating tissue specific hormone mechanisms. The company’s pipeline includes HSD17B1 inhibitor (phase I) for the treatment of endometriosis; dual HSD inhibitors (discovery) for the treatment of broader gynecological conditions; and Fispemifene (phase 2), a novel SERM for the treatment of male urological conditions. The company was founded in 2013 and is based in Turku, Finland.

MANAGEMENT TEAM

- Risto Lammintausta - Chief Executive Officer
- Janne Komi - Chief Medical Officer
- Maarit Merla - Head of Business Development

PIPELINE

- **Endometriosis**
  - HSD17B1 inhibitor, FDIII-6219

- **Women’s health indications**
  - Dual HSD inhibitor

- **Male urological conditions**
  - Fispemifene, selective estrogen receptor modulator
GamaMabs Pharma SA

COMPANY PROFILE

GamaMabs Pharma is a clinical-stage Biotechnology company developing optimized monoclonal antibodies in cancer.

GamaMabs' lead project, GM102, is an immuno-enhancer mAb in phase Ib/IIa in gynecological and colorectal cancers. It targets AMHRII/MISRII, a tumor-antigen expressed in a variety of cancers (gynecological cancers, CRC, NSCLC, HCC and RCC). GM102 reprograms tumor micro-environment macrophages restoring their anti-tumoral properties and subsequently re-activates T cells activity. Initial activity data have been generated in clinical trials.

GamaMabs follow-on programs include a 1st-in-class HER3 mAb and an ADC benefiting from a license and collaboration with Medimmune.

GamaMabs has raised so far €22m with leading European VCs (Andera Partners and Innobio-bpifrance).

MANAGEMENT TEAM

• Stéphane Degove – CEO and co-founder
• Jean-François Prost, MD – VP R&D and co-founder
• Isabelle Tabah-Fisch, MD – Chief Medical Officer
• Loan Hoang-SAyag, MD – VP Clinical Development

PIPELINE

Murlentamab (GM102)

Murlentamab (formerly GM102), is an immuno-enhancer mAb in phase Ib/IIa in gynecological and colorectal cancers. It targets AMHRII/MISRII, a tumor-antigen expressed in a variety of cancers (gynecological cancers, CRC, NSCLC, HCC and RCC). GM102 reprograms tumor micro-environment macrophages restoring their anti-tumoral properties and subsequently re-activates T cells activity. Initial activity data have been generated in clinical trials.

GM104

GM104 is an ADC targeting solid tumors in preclinical stages. GM104 benefits from a license signed with Medimmune on its Maia and PBD technologies.

HER3 program

9F7-F11 is a novel highly potent “allosteric anti-HER3 Ab” which binding to HER3 and effect on cell signaling are paradoxically facilitated by NRG and thus, exquisitely designed for NRG secreting tumors. In contrast to HER3 classical competitive antagonists, this original MOA translates into better efficacy of 9F7-F11 in in vivo models positive for NRG expression, and outstanding efficacy in NRG-rearrangement model.
Genclis SA

COMPANY PROFILE

Antibodies are the cornerstone of most immunological therapeutics that either block the function or accelerate the removal of unwanted proteins. Genclis SA, operates a technology platform that induces in various mammals high affinity antibodies directed toward any proteins irrespective of their origin –endogenous or exogenous- and of their intrinsic immunogenicity.

This platform relies primarily on Genclis proprietary discovery of a ubiquitous biological process –called transcription infidelity (TI) - that explains the divergences observed between RNA and DNA sequences. These divergences induce translational frameshifts on TI RNA that profoundly modify the immunogenic properties of their translated proteins. Specific TI events translate into proteins that cause production of immunoglobulin E (IgE), i.e. the antibody responsible for most forms of allergies. Others cause production of IgG that can be affinity matured, as already shown, to a level sufficient to suppress in vivo the function of a cytokine operating in the nanomolar range.

Genclis is currently engaged into two commercial strategic partnerships aiming at 1) producing a milk allergy prevention formula for high risk infants, that is obtained by removing low abundance milk TI proteins 2) achieving prolong itching suppression in dogs through simple immunization. These partnerships brought Genclis to profitability in 2018.

Genclis will diversify commercial partnerships in the broad field of prevention of allergies in human as well as expand veterinary therapeutic applications. The first veterinary program established so far the safety of the technology. Genclis is now able to develop on its own, manufacture and clinically validate specific immunization agents addressing currently unreachable medical targets.

Genclis programs are organized into 4 verticals –Virus, Bacteria, Parasites and Endogenous each covering specific clinical modalities. Genclis has therefore prioritized for the next 5 years selected medical targets using 4 criteria: market needs, availability of target biology intelligence, technological competitive advantage and market access velocity. The first two of these programs will enter clinical phases in 2020 and are aimed at causing 1) endogenous production of broadly neutralizing anti HIV antibodies 2) endogenous production of IgG blocking IgE binding to its receptor to alleviate severe clinical manifestations of allergy.

Genclis currently employs 28 people: 26 are scientists and engineers led by 6 PhD. Their credential is validated by more than 90 peer reviewed scientific communications and 3 main patent families covering respectively the discovery of TI (2007), the link between TI and immunity (2012) and the molecular origin of allergy (2015). Genclis has therefore prioritized for the next 5 years selected medical targets using 4 criteria: market needs, availability of target biology intelligence, technological competitive advantage and market access velocity. The first two of these programs will enter clinical phases in 2020 and are aimed at causing 1) endogenous production of broadly neutralizing anti HIV antibodies 2) endogenous production of IgG blocking IgE binding to its receptor to alleviate severe clinical manifestations of allergy.

Genclis intends to use the profits of existing and upcoming commercial partnerships to finance human clinical developments. Since incorporation in 2004, Genclis has raised 17 m€ in capital, received substantial award (1m€) and grants (2m€). In 2019, Genclis is willing to accelerate its clinical program expansion, structure its corporate organization and maintain its technological advance. To do so, Genclis is seeking the support of novel prominent institutional investors in order to accelerate and maximize and the value created by a highly disruptive technological breakthrough.

MANAGEMENT TEAM

- Bernard Bihain, MD, PhD, - CEO
- Sandrine Jacquenet, PhD, - Vice President of Allergy
- Virginie Ogier, PhD, - Vice President of Oncology
IGEM Therapeutics Ltd.

COMPANY PROFILE

IGEM Therapeutics is a UK Immuno-Oncology company developing novel IgE antibodies to treat cancer. IgE has evolved to kill tissue-dwelling multicellular parasites endowing it with several key features that make it ideal for the treatment of solid tumours which also mostly reside in tissue. The epsilon constant region of IgE binds very tightly to its cognate receptor (FcεRI) on the surface of immune effector cells including macrophages, monocytes, basophils and eosinophils. This interaction is up to 10,000 fold greater than the gamma chain of IgG has for its equivalent receptor and this results in the majority of IgE molecules being permanently attached to the surface of immune effector cells. The latter are therefore primed and ready to destroy cells expressing the antigen recognised by the IgE. As a result, IgE is able to permeate tissues more effectively than IgG and stimulate significantly greater levels of both ADCP (antibody-dependent cell-mediated phagocytosis) and ADCC (antibody-dependent cell-mediated cytotoxicity), the two main mechanisms by which immune effector cells can kill tumour cells. IgE also has a significantly longer tissue half life than IgG (2 weeks versus 2 – 3 days) which also suits it for a role in the destruction of solid tumours.

The company’s lead programme targets the folate receptor alpha (FR alpha) and an anti-FR alpha IgE antibody is currently in a phase 1/2a trial to treat ovarian cancer. This is the world’s first IgE therapeutic to enter the clinic.

IGEM is also developing a novel antibody platform technology based on protein and glyco-engineering of the epsilon constant region.

MANAGEMENT TEAM

- Tim Wilson - Chief Executive Officer
- Vivienne Cox - Chief Operating Officer
- Kevin FitzGerald - Chief Scientific Officer
- Phil Boyd - Chief Financial Officer

PIPELINE

<table>
<thead>
<tr>
<th>PRODUCT</th>
<th>INDICATION</th>
<th>STATUS</th>
</tr>
</thead>
<tbody>
<tr>
<td>IGEM-F*</td>
<td>Ovarian, breast, lung</td>
<td>PC, Ph 1, Ph 2, Ph 3, Market</td>
</tr>
<tr>
<td>IGEM-FR</td>
<td>Ovarian, breast, lung</td>
<td>PC, Ph 1</td>
</tr>
<tr>
<td>IGEM-Ch</td>
<td>Melanoma, TNBC</td>
<td>PC, Ph 1</td>
</tr>
<tr>
<td>IGEM-H</td>
<td>Breast, gastric</td>
<td>PC, Ph 1</td>
</tr>
</tbody>
</table>

*IGEM has an exclusive option on IGEM-F from King’s College London. IGEM-F is currently in a phase 1 trial in ovarian cancer sponsored by Cancer Research UK.
Imcyse SA

COMPANY PROFILE

Imcyse develops active targeted immunotherapies to treat and prevent severe chronic diseases caused by dysregulations of the immune system.

The company’s unique active immunotherapy technology platform allows it to destroy locally the immune cells involved in the destruction of the diseased organ. This platform is based on the administration of Imotopes™, which are specific modified peptides, allowing for the generation of a new type of T-cell, called cytolytic CD4. Imcyse’s approach, sustained over time, helps to prevent and treat diseases with no current therapeutic alternative and to cure the patient without impairing immune defenses.

The company has established proof of concept in type 1 diabetes, multiple sclerosis, myasthenia gravis, allergy and prevention of immunogenicity to viral vectors and is running its first clinical trial in type 1 diabetes in seven European countries.

Other projects, which address multiple sclerosis, rheumatoid arthritis and neuromyelitis optica, are at preclinical, proof-of-concept and research stages, respectively.

Founded in 2010, Imcyse is a spin-off from the Katholieke Universiteit Leuven (KUL), Belgium. The company is based near the Belgian city of Liège. It is managed by a small group of pharmaceutical industry experts.

MANAGEMENT TEAM

- Pierre Vandepapelière, MD, PhD - CEO and CMO
- Jean Smal, PhD - Senior Advisor, Development and Manufacturing
- Marcelle Van Mechelen - PhD, Senior Scientific Advisor, Immunology
- Jean Van Rampelbergh - PhD, Clinical & Regulatory Director
- Guillaume de Viron - CFO
- Vincent Carlier, PhD - Head of Immunology
- Luc Vander Elst, PhD - Head of Imotope Development & in vivo
- Yves Lobet, PhD - Portfolio Director
- Marie Gérard - Head of corporate affairs
- Geoffrey Gloire - PhD, IP Manage

PIPELINE

Imcyse’s Imotopes: Pipeline & Status
Immune System Key (ISK) Ltd.

COMPANY PROFILE

Immune System Key Ltd. (ISK) is a privately held company that was founded in 2005 by Prof. Uziel Sandler and Dr. Yoram Devary.

The company is engaged with developing of its drug candidate Nerofe TM. Nerofe TM acts through a novel MOA that serves as the basis for the personalized anti-cancer immunotherapy technology developed by ISK Ltd. Our anti-cancer immunotherapy technology synergizes well with anti-PD1/PDL1 technology.

The company has successfully finished Phase 1 trial and is now aiming three Phase 2 clinical trials in the USA.

NerofeTM was granted by the FDA with orphan drug designation for AML treatment. The company holds 3 worldwide patents on the molecule and applications.

We are looking for collaborations and investments to keep on developing our anti-cancer technology.

MANAGEMENT TEAM

- Dr. Yoram Devary - Founder, Chairman and CTO
- Prof. Uziel Sandler - Founder, Vice-Chairman and CEO

PIPELINE

1. Phase 2 trial of Nerofe for treatment of (ST2+) AML patients
2. Phase 2 trial of Nerofe for treatment of (ST2+) mCRC patients and (ST2+) pancreatic cancer patients
3. Phase 2 trial of Nerofe for the treatment of (ST2+) ovarian cancer patients and TNBC patients.
InCarda Therapeutics, Inc.

COMPANY PROFILE

InCarda Therapeutics, Inc. is a privately-held, clinical-stage biopharmaceutical company pioneering a novel approach of treating cardiovascular conditions by the inhalation route. The advantage of inhalation is that it delivers medicine in the “first pass” to cardiac tissue, presenting a small, but effective dose of drug directly to affected regions of the heart. This permits rapid-onset, lower off-target tissue exposure of the drug, lower continued/prolonged exposure to cardiac tissue and, more importantly, can be patient self-administered anywhere PAF episodes may occur.

The lead product under development is an inhaled therapy to treat paroxysmal atrial fibrillation (PAF), a widespread atrial arrhythmia. InCarda employs a de-risked approach by using approved drugs with a long history of efficacy and safety in a new dosing paradigm.

We are a team of highly-experienced, passionate teammates who have a strong track record of development. We are also supported by a world-class group of experts and advisors.

MANAGEMENT TEAM

- Grace E. Colón, Ph.D. - President & Chief Executive Officer
- Luiz Belardinelli, M.D. - Chief Medical Officer
- Carlos Schuler, Ph.D. - Chief Operating & Technology Officer & Co-Founder
- Guy Anthony - Chief Financial Officer*
- Margaret Dillon, Ph.D. - Senior Vice President, - Regulatory Affairs
- Debra S. Echt, M.D. - Senior Vice President, - Medical Affairs*

PIPELINE

<table>
<thead>
<tr>
<th>Product Candidate</th>
<th>Preclinical</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>Regulatory Approval</th>
</tr>
</thead>
<tbody>
<tr>
<td>InRhythm™ under Medical Supervision:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>INSTANT Phase 2 Trial</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>InRhythm™ for Patient Self-Administration</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(At-Home, Out of Hospital)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>InRhythm™ for PSVT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Confidential Cardiovascular &amp; Inhalation Programs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
IO Biotech ApS

COMPANY PROFILE

IO Biotech is founded on ground breaking research from the Center for Cancer Immune Therapy (CCIT) in Copenhagen Denmark, identifying and characterizing intrinsic T-cells specific for immune suppressive proteins like IDO, TDO and Arginase. When boosted in vivo, these T-cell address both the tumor and the tumor microenvironment by eliminating cancer cells and immune suppressive cells.

Our T-win® platform leverages well-documented and safe peptide-based vaccine modalities to engage and activate these intrinsic T-cells raising powerful anti-tumor responses in situ. This makes IO Biotech uniquely positioned to capitalize on the vast amount of research describing the abundance of these immune suppressive molecules in cancer and their role in the tumor microenvironment and tumor escape.

We currently have six preclinical and clinical programs in our pipeline suitable for single agent or combination treatment

IO Biotech’s first immune modulatory vaccine, targeting IDO, showed promising efficacy in 15 heavily pretreated NSCLC patients (mOS of 25.9 months), with 3 patients still alive now 6 years after initiation of treatment, hereof 2 without any new subsequent anti-cancer therapy.

We have completed the safety run in in a global phase 2 trial with a second generation IDO vaccine. This collaborative trial with Merck/MSD is investigating our vaccine in first line NSCLC setting in combination with Keytruda®.

Promising efficacy and significant T-cell influx in the tumor and remodulation of TME is seen with vaccine combining PD-L1 and IDO with nivolumab in anti PD-1 naïve metastatic melanoma.

MANAGEMENT TEAM

- Mai-Britt Zocca - Chief Executive Officer
- Mads Hald Andersen - Chief Scientific Officer
- Eva Ehrnrooth - Chief Medical Officer
- Soren Bregenholt - Chief Business Officer
- Mikkel Dybkjaer - Chief Financial Officer

PIPELINE

IO102 is a first-in-class, second generation immune modulatory vaccine containing a single IDO-derived peptide sequence designed to engage and activate IDO specific human anti-regulatory T-cells.

IO102 is currently being tested in two clinical trials: A randomized phase I/II trial in combination with KEYTRUDA® (pembrolizumab) standard-of-care in first-line treatment of patients with metastatic Non-small Cell Lung Cancer (NCT03562871) and a non-randomized phase I/II trial in combination with IO103 and Opdivo® (nivolumab) in both treatment-naïve and PD-1/PD-L1 mAb refractory patients with Metastatic Melanoma (NCT03047928).

IO103 is a first-in-class, immune modulatory vaccine containing a single PD-L1-derived peptide designed to engage and activate PD-L1 specific human anti-regulatory T-cells. IO103 is being tested in a single arm phase I/II trial assessing IO103 as monotherapy in patients with Basal Cell Carcinoma of the skin (NCT03714529).

IO112 is a first-in-class, immune modulatory vaccine containing arginase derived peptide(s) designed to engage and activate arginase specific human anti-regulatory T-cells. IO112 is being tested in a single arm phase I trial in patients with arginase-positive solid tumors (NCT03689192).
**IO140** is a first-in-class, immune modulatory vaccine containing a single CCL22 derived peptide designed to engage and activate CCL22-specific human anti-regulatory T-cells. IO140 is currently in preclinical development.

**IO160** program is a first-in-class vaccine containing a single CalR-derived peptide designed to engage cytotoxic T-cells specific for the mutation in exon 9 of CalR. IO160 is being tested in a single a single arm phase I clinical trial in MPV patients with CalR exon 9 mutations (NCT03566446).

<table>
<thead>
<tr>
<th>Target</th>
<th>Program</th>
<th>Indication</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
</tr>
</thead>
<tbody>
<tr>
<td>IDO</td>
<td>IO102</td>
<td>NSCLC frontline + PD-1 mAb + CT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PD-L1</td>
<td>IO103</td>
<td>Basal Cell Carcinoma before surgery</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IDO + PD-L1</td>
<td>IO102+IO103</td>
<td>Melanoma frontline + PD-1 mAb</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arginase</td>
<td>IO112</td>
<td>Solid tumors relapsed/refractory</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CCL22</td>
<td>IO140</td>
<td>Ovarian Cancer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neo-antigen</td>
<td>IO160</td>
<td>MPN with CalR exon9 mutation</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Medherant Ltd.

**COMPANY PROFILE**

Medherant is a clinical-stage company developing innovative products for pain and CNS diseases by leveraging our unique TEPI® technology to deliver approved drugs in a better way via drug-in-adhesive patches. Our business model is to develop our own products, which we will license for commercialisation, and also to work with pharmaceutical company partners to formulate their products as TEPI Patches.

Two Phase I studies were successfully completed in 2018 with the ibuprofen TEPI Patch. These studies demonstrated that TEPI Patch technology is well-tolerated and can deliver the expected level of drug. The ibuprofen TEPI Patch is now available for licensing.

Medherant is developing a pipeline of products that it intends to develop through the relatively inexpensive and rapid bioequivalence route. These products include a cannabinoid and two drugs for Alzheimer’s disease.

Delivery of drugs using patches that are applied to the skin can avoid problems associated with the oral route, such as gut toxicity, poor bioavailability and peaks and troughs in blood levels. Patches also provide better dose control than gels and creams. However, the currently available technologies are not ideal for many drugs. Medherant’s TEPI Patch technology is a next-generation patch technology that enables thin, flexible, patient-friendly patches to be made for a wide variety of small molecule drugs. Medherant is already engaged in collaborations with pharmaceutical companies with a view to developing TEPI Patch formulations of their molecules of interest.

TEPI Patches use a proprietary novel pressure-sensitive adhesive that has been exclusively licensed from Bostik. The technology is protected by over 85 granted patents, as well as recent patent applications. The company has its own pilot plant and high throughput system for testing transdermal product formulations.

**MANAGEMENT TEAM**

- Ken Cunningham - Non-Executive Chairman
- Mark Payton - Mercia Fund Management (Nominees) Ltd
- Quentin Compton-Bishop - Representing the University of Warwick
- Nigel Theobald - Non-Executive Director
- Nigel Davis - Chief Executive Officer
- David Haddleton - Chief Scientific Officer
- Sally Waterman - Chief Operating Officer
- Andrew Lee - Director of Commercial Development

**PIPELINE**

- **Product 1**
  Dronabinol TEPI Patch for chemotherapy-induced nausea and vomiting
  Formulation optimisation

- **Product 2**
  Memantine TEPI Patch for Alzheimer’s disease
  Formulation optimisation

- **Product 3**
  Donepezil TEPI Patch for Alzheimer’s disease
  Formulation optimisation
Metabomed Ltd.

COMPANY PROFILE

Metabomed is a drug discovery company in the field of cancer metabolism. The company is developing a proprietary target identification platform based on computational biology, genomics and metabolomics. The platform identifies metabolic pathways that arise uniquely in cancers and are essential for their growth. These discoveries are used to develop small molecules that specifically target the reprogrammed cancer cells’ metabolism to halt their growth. Since these molecules inhibit divergent pathways that are specific to cancer cells, these therapies will not damage healthy surrounding tissues.

Metabomed is a privately held company based in Israel and supported by the groundbreaking science of its scientific founders.

MANAGEMENT TEAM

- Dr. Simone Botti - Chief Executive Officer
- Dr. Andreas Goutopoulos - Chief Scientific Officer
- Dr. Omri Erez - Vice President, Biology
- Dr. Philippe Nakache - Vice President, Chemistry

PIPELINE

Our pipeline includes drugs aimed at first-in-class targets that are synthetically lethal with the loss of the following metabolic enzymes: Fumarate Hydratatse (FH), Succinate Dhydrogenase (SDH) and Methylthioadenosine Phosphorylase (MTAP). Although SDH and FH are “housekeeping genes” with key bioenergetic roles, they are also known to be tumor-suppressing genes. The loss of their function results in cancer, specifically in the kidney and in the GI tract. MTAP function is lost in about 15% of all cancers. This percentage grows to 55% of Glioblastoma and up to 25% Pancreatic Adenocarcinoma, two especially aggressive and hard to treat cancers.
MGC Pharmaceuticals (UK) Ltd.

COMPANY PROFILE

MGC Pharmaceuticals Ltd (ASX: MXC OTCUS: MGCLF) is a European-based specialist Medical Cannabis company and an international pioneer in Phytocannabinoid-based medicine within the biopharmaceutical industry.

Heralding countless years of practical, scientific and business experience, MGC Pharma’s founders are all prominent leaders in the Global Medical Cannabis industry.

MGC Pharma’s principal business goal is to produce and supply high quality Phytocannabinoid based pharmaceutical products (Phytomedicines and Phytotherapeutics) for the medical markets of Europe, North America and Australasia.

MANAGEMENT TEAM

- Nativ Segev – Founder, Managing Director
- Roby Zomer – Co Founder & Managing Director
- Dr. Jonathan Gruenfeld – Chief Scientific Officer
- Ron Lipsky – VP International Business Development

PIPELINE
Mymetics SA

COMPANY PROFILE

Mymetics is a Swiss based biotechnology company, with a Research Lab in the Netherlands focussed on development of vaccines and immunotherapies based on our proprietary virosome platform. Our vaccines are designed to induce protection against early transmission and infection, focusing both on the mucosal immune response as a first-line defense and the systemic humoral (blood) immune response. Our unique approach has resulted in the development of a rich pipeline of vaccine candidates for HIV-1/AIDS, intra nasal Influenza, Malaria, RSV and Chikungunya and some early data in the Allergy and Oncology immunotherapy field. Our delivery platform is being validated through partnerships with leading pharmaceutical or research organisations, including Sanofi, PATH-MVI and the Bill and Melinda Gates Foundation. The company is registered in the US and trades on the OTCQB, venture stage market place – fully SEC compliant.

MANAGEMENT TEAM

- Ronald Kempers - President, CEO and CFO
- Dr. Mario Amacker - Head of Quality and Manufacturing
- Dr. Sylvain Fleury - Chief Scientific Officer
- Dr. Toon Stegmann - Chief Scientific Officer Mymetics BV – Head R&D

PIPELINE

- Virosomes are enveloped virus-like particles
- Virosomes lack the genetic material of the native virus: virosomes are non-infectious
- Retain the receptor-binding and membrane fusion function of the virus (elicits CD8+ T cells)
- Antigens and adjuvant can be incorporated in virosomal membrane, targeting these to antigen-presenting cells, all on one particle
- Excellent Safety and Tolerance profile
- Up-scalable, GMP manufacturing record and low COGs

<table>
<thead>
<tr>
<th>Infectious Diseases</th>
<th>Discovery</th>
<th>Preclinical</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
<th>Partners</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malaria</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Influenza</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chikungunya</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RSV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Allergy Immune therapy</th>
<th>Discovery</th>
<th>Preclinical</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
<th>Partners</th>
</tr>
</thead>
<tbody>
<tr>
<td>Birch Pollen</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Anergis</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Immune Oncology</th>
<th>Discovery</th>
<th>Preclinical</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
<th>Partners</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exploring</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Oryzon Genomics S.A.

COMPANY PROFILE

Oryzon is a public clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics.

From its founding in 2000 through 2008, the company focused its efforts in growing a functional genomics platform business model. In 2008, with the acquisition of Crystax Pharma, we started our drug discovery programs in oncology and neurodegenerative diseases. Our business model is to develop our proprietary drug candidates till mid clinical stage, at which point it is decided on a case-by-case basis to either keep the development in-house or to partner or outlicense the compound for late stage development and commercialization.

Oryzon is listed on the Spanish Stock Exchange since December 2015 (ORY, ISIN Code: ES0167733015). In the period 2015-2016, the company raised €32M, with additional PIPEs in 2017 (€18.2M) and 2018 (€13M) where the company incorporated specialized investors from US and Europe.

The company has a broad and growing portfolio, with two compounds in clinical trials, ladademstat (ORY-1001), a highly potent and selective LSD1 inhibitor that has been granted orphan-drug status by EMA, in Phase IIA in oncology, and Vafidemstat (ORY-2001), a LSD1/MAO-B inhibitor, also in Phase IIa, dual for the treatment of mild to moderate Alzheimer’s disease, multiple sclerosis. Vafidemstat is also being explored in a basket trial to treat aggressiveness in psychiatric conditions like ASD, ADHD, and BLP and other neurodegenerative diseases. The company has another compound ready to start Phase I, ORY-3001, a selective LSD1 inhibitor for the treatment of non-oncological diseases, and additional earlier programs in other cancer indications.

From 2014 to 2017 the company had a collaboration with Roche relating to our lead oncology program and received +$23M. This asset is now being developed by Oryzon. The company has also obtained competitive US and European grants in the amount of €8M to support the development of Vafidemstat (ORY2001) since the start of our CNS research.

The company has a seasoned executive management with vast experience in the industry.

MANAGEMENT TEAM

- Carlos Buesa - Chief Executive Officer
- Tamara Maes - Chief Scientific Officer
- Roger Bullock - Chief Medical Officer
- Michael T Ropacki - Chief of Clinical and Product Development
- Sonia Gutierrez - Chief of Clinical Operations
- Enric Rello - Chief Operating Office, Chief Financial Officer in Spain
- Emili Torrell - Chief Business Development Officer
- Neus Virgili - Chief Intellectual Property Officer

www.sachsforum.com
# Oryzon Pipeline

<table>
<thead>
<tr>
<th>Indication</th>
<th>Study</th>
<th>Research</th>
<th>Preclinical</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
</tr>
</thead>
<tbody>
<tr>
<td>VAFIDEMSTAT (ORY-2001) - dual LSD1-MAO B inhibitor</td>
<td>ETERAL monotherapy (*)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alzheimer’s disease (Mild Moderate)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multiple Sclerosis (Relapse Remitting &amp; Secondary Progressive)</td>
<td>SATEEN monotherapy (*)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CNS Basket Trial Aggression</td>
<td>REIMAGINE monotherapy (*)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IADADEMSTAT (ORY-1001) - selective LSD1 inhibitor</td>
<td>ALICE Combo w Aza (*)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AML (Elderly Unfit)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SCLC (First Line Relapsed)</td>
<td>CLEPSIDRA Combo w Platinum/Etoposide (*)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ORV-3001 - selective LSD1 inhibitor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non Oncological</td>
<td>Preclinical finished</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OTHER PROGRAMS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Undisclosed</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(*) Approved, Recruitment ongoing
(1) Approved
(2) CTA submitted
PDC*line Pharma SA

COMPANY PROFILE

Founded in April 2014 as a spin-off of the French Blood Bank (Etablissement Français du Sang, EFS), PDC*line Pharma is a Belgian-French biotech company that is developing a novel class of off-the-shelf cancer immunotherapies based on a proprietary Plasmacytoid Dendritic Cell line (PDC*line) loaded with HLA-A2-restricted peptides that are derived from target tumor antigens. Our breakthrough technology, PDC*vac is highly potent in priming and boosting fully functional antitumor CD8+ T cells displaying a strong cytotoxic activity against tumor cells. It is more easily scalable, more versatile and more potent than other dendritic-cell-based vaccines, and it is synergetic with the use of anti-PD-1 immune checkpoint inhibitors.

PDC*line is a professional and universal antigen-presenting cell very easy to expand in large quantities in bioreactors and having been exposed in vitro to targeted tumor antigens and irradiated, it can be stored for years. The off-the-shelf product is thawed and injected to treat any patients with a cancer type expressing the selected antigens and expressing HLA-A2. Of note, different HLA may be used or added to extend the target population. PDC*vac currently comes in the form of several cancer vaccine drug products: PDC*lung: our leading candidate for non-small-cell lung cancer (NSCLC). PDC*neo: our next candidate. It is currently being developed at the preclinical stage. A first pilot academic clinical trial with our first candidate for melanoma has been completed in 2017 demonstrating the safety of the product, the absence of rejection and its biological activity. PDC*line Pharma is headquartered in Liège (Belgium), comprises a team of 19 persons, has raised nearly €15 M in equity and non-dilutive funding and is preparing a new round of financing.

MANAGEMENT TEAM

- Eric Halioua (MS, MBA) – President & Chief Executive Officer
- Laurent Levy (MS, Exec. MBA) - Co-founder & Chief Operating Officer
- Joel Plumas (PhD) - Co-founder & Chief Scientific Officer
- Claude Dedry (Pharm. D) - VP Pharmaceutical Operations & Quality

PIPELINE

Our lead candidate, PDC*mel, is currently in the phase 1 first-in-human clinical trial for advanced melanoma. PDC*lung is starting clinical development for lung cancer.
perora GmbH

COMPANY PROFILE

We have developed - and clinically validated - the first effective non-pharmaceutical oral therapy for diabetes type II. A first clinical study has just been completed, and we are now preparing to launch the product as nutritional supplement with health claim in Germany. Mode of action is blunting of postprandial glucose peaks.

We are aiming for commercialization to diabetes centers in Germany and directly to patients through online marketing. We see great potential in integrating the product in a patient-centric digital health environment.

MANAGEMENT TEAM

• Dr. Dirk Vetter - CEO
• Dr. Schmidt - COO
• Frank Parotta - CBO

ADDRESS
Im Neuenheimer Feld 518
69120, Heidelberg
Germany

WEBSITE
www.perora.com

E-MAIL
eemail@perora.com

PHONE
+49 6221 4344

COMPANY TYPE
Private

SECTOR
Diabetes Type II
Metabolic Diseases

FOUNDED
2013
Pharmaleads SA

COMPANY PROFILE

Pharmaleads aims to provide patients suffering from severe chronic and acute pain with improved pain relief without the side effects associated with other classes of analgesics.

Based on years of experience in the design of highly potent and specific inhibitors of enkephalinases, Pharmaleads has developed a new class of analgesics called DENKIs (Dual Enkephalinases inhibitors). These small molecules are able to provide patients with local and sustainable pain relief.

Pharmaleads’ DENKIs are first-in-class drugs with a novel mechanism of action tackling pain by using endogenous enkephalins, natural peptides that specifically bind to pain-related opioid receptors to naturally modulate pain without the side effects observed with exogenous opioid drugs that also bind to other opioid receptors, not involved in pain control and thus triggering multiple side effects.

Pharmaleads believes its products can change the lives of the many patients in need of improved treatment options for their chronic and/or acute pain, and could offer healthcare providers with a safe pain management option that helps address the opioid epidemic.

MANAGEMENT TEAM

• Thierry Bourbié, Co-Founder, Chief Executive Officer & Chairman
• Pierre Maillard, Chief Financial Officer
• Michel Wurm, VP, Medical Affairs, Strategy & Business Development
• Tanja Ouimet, Director of Clinical Development
• Hervé Poras, Director of CMC and Preclinical Operations

PIPELINE

<table>
<thead>
<tr>
<th>PRODUCT/INDICATION</th>
<th>DEVELOPMENT PHASE</th>
</tr>
</thead>
<tbody>
<tr>
<td>PL37</td>
<td></td>
</tr>
<tr>
<td>MIGRAINE Oral route</td>
<td>DISCOVERY</td>
</tr>
<tr>
<td>POST-SURGICAL PAIN I.V.</td>
<td>PRE-CLINICAL</td>
</tr>
<tr>
<td>NEUROPATHIC PAIN Oral route</td>
<td>PHASE 1</td>
</tr>
<tr>
<td>OCULAR PAIN/DED Eye drops</td>
<td>PHASE 2</td>
</tr>
<tr>
<td></td>
<td>PHASE 3</td>
</tr>
</tbody>
</table>
Polyphor Ltd.

COMPANY PROFILE

We are an innovative biopharmaceutical company with two Phase III Products. We pioneered the development of “OMPTA” (Outer Membrane Protein Targeting Antibiotics), potentially the first new class of antibiotics against Gram-negative bacteria in 50 years. Murepavadin, the first OMPTA, is in Phase III development for nosocomial pneumonia from *Pseudomonas aeruginosa* infections, addressing an overall market opportunity estimated in a USD 2-3 billion range.

Our immuno-oncology drug, Balixafortide, demonstrated proof of concept and has started the pivotal study agreed with FDA and EMA in HER2-negative metastatic breast cancer. It has Fast Track status with the FDA. The estimated market potential of this drug is USD1.3-1.4 billion in combination with eribulin and substantially more if expanded to other combinations and indications.

MANAGEMENT TEAM

- Giacomo Di Nepi, MBA, MSC - Chief Executive Officer
- Frank Weber, M.D. - Chief Medical & Development Officer ad-interim
- Daniel Obrecht, Ph.D. - Chief Scientific Officer
- Kalina Scott - Chief Financial Officer
- Helmut Kessmann, Ph.D. - Head of Business Development Pharma
- Franziska Müller - Head of Human Resources

PIPELINE

**Antibiotics**

Murepavadin (POL7036) – *Pseudomonas infections* >

<table>
<thead>
<tr>
<th>Stage</th>
<th>Discovery</th>
<th>Preclinical</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
<th>Approval</th>
</tr>
</thead>
</table>

OMPTA platform – targeting Gram-negative resistant pathogens >

Lead preclinical compound: POL7306

<table>
<thead>
<tr>
<th>Stage</th>
<th>Discovery</th>
<th>Preclinical</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
<th>Approval</th>
</tr>
</thead>
</table>

**CXCR4 antagonist**

Balixafortide (POL6326) – for novel immune-oncology agent for combination therapy >

Fast Track Designation granted by FDA

<table>
<thead>
<tr>
<th>Stage</th>
<th>Discovery</th>
<th>Preclinical</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
<th>Approval</th>
</tr>
</thead>
</table>

**Inhaled elastase inhibitor**

POL6014 – Cystic Fibrosis >

<table>
<thead>
<tr>
<th>Stage</th>
<th>Discovery</th>
<th>Preclinical</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
<th>Approval</th>
</tr>
</thead>
</table>

Cut off compliance to Santheris Pharmaceuticals
14.02.2018
Silenseed Ltd.

COMPANY PROFILE

Silenseed LTD is a clinical stage biopharmaceutical company that is developing proprietary RNA interference (RNAi)-based cancer drugs and delivery systems designed to effectively penetrate and treat malignant solid tumors. The company’s novel drugs, used together with the new delivery system, the LODER™ (LOcal Drug EluteR), have the potential to be one of the most highly effective treatments for solid tumor cancers. Diseases that currently are included in the company’s pipeline are pancreatic cancer, prostate cancer and certain brain cancers.

MANAGEMENT TEAM

• Amotz Shemi, PhD - CEO
• Cheli Gonnen - VP Clinical Affairs
• Ettie Pirak, PhD - Director, Drug Development
• Asher Shamir, CPA - VP Finance
• Yafit Stark, PhD - Global Clinical Development Strategy

PIPELINE

- si-GAL-LODER (Pancreatic Cancer)
- si-PT-LODER (Prostate Cancer)
- si-GMCI-LODER (Brain Cancer)
Stalicla SA

COMPANY PROFILE

STALICLA is an autism spectrum disorder (ASD) focused, data guided, drug development biotech company. Through an innovative systems biology-based platform (DEPI), STALICLA has been able to identify non-behavioral subgroups of patients with idiopathic ASD and corresponding first-in class treatment candidates, thus pioneering personalized medicines for ASD.

KEYPOINTS

- Q1 2018 successful closure of CHF 4M seed round
- Development of a strong ecosystem with Key Opinion Leaders in the field of ASD
- February 2018, STALICLA listed among the top 50 startups in Switzerland (Business magazine BILAN classification)
- March 2018, first clinical validation of the ASD Ph1 subgroup through observational clinical trial at the Greenwood Genetic Center (SC, USA)
- April 2018, listing of STALICLA among emerging biotech to follow by Canaccord Genuity, a global financial services firm with strong focus on healthcare sector
- May 2018, official launch of STALICLA’s clinical development program
- July-August 2018, results supporting specific biological profile in ASD phenotype 1 vs other patients with ASD vs controls. Potential for first in class biomarker in idiopathic Autism Spectrum disorder
- October-November 2018, Incorporation of STALICLA’s Computational Systems Biology physical HPC unit in Barcelona, Spain – incl. 4 FTE computational biology data scientists.
- November 2018, international patent applications, request for examination of the STP1 COM patent in USA, EU and other countries, filling new EU patent application and US provisional patent on specific metabolomic profile of ASD Ph1 patients’ cells.
- November 2018, first results supporting efficacy of STP1 on metabolomic profile of ASD Ph1 patients’ cells.
- December 2018. final closure of STALICLA Series A1 for a total amount of CHF 10 M

MANAGEMENT TEAM

- Lynn Durham – MSc – CEO & Founder
- Jean-Marc Hyvelin - PhD - Chief Operation Officer
- Xavier Liogier D’Arthuy - PhD - Chief of Translational Development
- Luigi Boccuto- MD – Chief Scientific Officer
- Walter Kaufmann - MD - Senior Clinical Scientist
- Joseph Wettstein – PhD – Acting Chief of Development and Strategy

PIPELINE
Symphogen A/S

COMPANY PROFILE

We develop innovative antibody therapies for the treatment of cancer and other significant diseases.

Symphogen is a clinical-stage antibody company with a differentiated product pipeline and significant commercial opportunities. Our antibody platform and capabilities provide a strong foundation for continued discovery and development of innovative product candidates.

MANAGEMENT TEAM

- Martin Olin, EMBA, M.Sc. - Chief Executive Officer
- Mads Laustsen, M.Sc. - Chief Manufacturing Officer
- Ivan D. Horak, MD, FACP - Executive Consultant
- Jesper Bramming, M.Sc. Economics - Chief Financial Officer

PIPELINE

We have a broad and differentiated clinical pipeline of multiple product candidates, each for multiple indications. Our pipeline includes two partnered clinical-stage programs and our platform continues to deliver innovative antibody-based product candidates.
Two To Biotech Ltd.

COMPANY PROFILE

Two To Biotech Ltd. is a privately held biotech company established in 2007 engaged with the discovery of novel human peptide hormones and development of mAb against novel human targets.

The peptide hormones we have discovered are for treatment of oncology indications and some for treatment of diabetes and other metabolic disorders.

The different peptide hormones were discovered by using the company’s revolutionary technology platforms for the discovery of novel human peptide hormones, receptors, and enzymes.

Our technologies are the first in the world that allows 3D-protein structure screening of the human genome, so we are not limited to any sequence. This approach allowed us to identify many novel proteins never discovered.

We are looking for collaborations and investments to discover and develop new targets in the area of immune regulation of cancer, regulation of body weight and metabolism.
UGISense AG

COMPANY PROFILE

UGISense AG is a biotech company dedicated to developing new and innovative antisense therapeutic agents in collaboration with partners from the industry and academia. The developments are made on the basis of a proprietary platform technology, i.e. the UgimeresTM. The company, which was first established in 2016, is being financed by private investors and has been accredited by the Federal Office of Economics and Export Control (BAFA) (within the scope of their Funds for Venture Capital program).

MANAGEMENT TEAM

- Thomas Lindhorst - Managing Director
- Birgit Werner - Managing Director

TECHNOLOGY

Ugimers™

UgimeresTM are short oligonucleotide sequences capable of interacting with single-stranded DNA or RNA by forming a double strand. Thanks to said double-strand formation, disease-relevant proteins will be specifically prevented from forming altogether or will be reduced to only a modified stage. This makes it possible to therapeutically influence the development of diseases at a very early stage of intervention. Structurally, UgimeresTM are derived from peptide nucleic acids (PNAs) to which important pharmacological functions have been added by way of chemical modifications.
VAXIMM

COMPANY PROFILE

VAXIMM is a privately held, clinical stage, Swiss/German biotech company developing oral T-cell immunotherapies for patients suffering from cancer.

VAXIMM’s technology is based on first-in-class oral T-cell activators using modified attenuated bacteria that can be readily adapted to target a wide range of cancer-related antigens.

The Company’s lead product candidate, oral VXM01, currently in clinical trials, activates killer T-cells targeting tumor vasculature and certain immune-suppressive cells and causes increased inflammation in solid tumors.

VAXIMM completed Phase I/II trials of VXM01 in advanced pancreatic cancer and metastatic colorectal cancer. Clinical trials are ongoing in recurrent glioblastoma (brain cancer) including a recently started checkpoint inhibitor combination study in collaboration with Merck/Pfizer.

The Company has several additional product candidates at various stages of preclinical development. These candidates can be developed as stand-alone therapies or in combination with other immunotherapies, including VXM01.

Investors in our company include: BB Biotech Ventures, M Ventures, Sunstone Capital, BioMed Partners, and CMS Medical Venture.

VAXIMM AG is headquartered in Basel, Switzerland with a wholly owned subsidiary, VAXIMM GmbH (Mannheim, Germany), from where the Company’s development activities are orchestrated, and a laboratory in Regensburg, Germany.

MANAGEMENT TEAM

- Thomas Hecht, MD - Executive Chairman
- Heinz Lubenau, PhD - Chief Operating Officer
- Marc Mansour, PhD, MBA - Chief Business Officer

PIPELINE

A first-in-human study in pancreatic cancer and a study in metastatic colorectal cancer patients were successfully completed.

1 scientific collaboration
Emerald Health Pharmaceuticals, Inc.
emeraldpharma.life

Emerald Health Pharmaceuticals is focused on treating life-threatening diseases through cannabinoid science. By combining decades of life science and drug development experience with industry-leading expertise in cannabinoid science, EHP is discovering, developing and commercializing proprietary cannabinoid-derived medicines that address significant unmet needs. Currently, EHP is advancing two families of new chemical entities (NCE), derived from cannabidiol (CBD) and cannabigerol (CBG) that it has modified through rational drug design to affect validated receptors pertinent to targeted diseases. Its lead drug candidate, EHP-101, a synthetic derivative of CBD, is focused on treating multiple sclerosis and scleroderma. Its second, EHP-102, a synthetic derivative of CBG, is focused on treating Huntington’s disease and Parkinson’s disease. The company intends to launch a Phase I clinical study of EHP-101 in 2018.

Euronext
www.euronext.com

Euronext is the leading pan-European exchange in the Eurozone, covering Belgium, France, Ireland, The Netherlands, Portugal and the UK. With 1,300 listed issuers worth €3.4 trillion in market capitalisation as of end December 2018, Euronext is an unmatched blue chip franchise that has 24 issuers in the Morningstar® Eurozone 50 Index and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, Euronext also operates Euronext Growth™ and Euronext Access™, simplifying access to listing for SMEs.

Torreya Partners Europe LLP
www.torreya.com

Torreya Partners LLP is a leading boutique advisory firm that provides strategic advice and assistance with Mergers & Acquisitions, Partnering and Financings to life science companies worldwide. Torreya Partners provides the long-term thinking and objective advice required for life science companies to create lasting value. We take great pride in handling complex financial and strategic matters for some of the most sophisticated private and public life science companies in the world. Our reputation has been built on quality advice, excellence in deal execution and good outcomes for our clients. We bring the caliber of people and quality of relationships found in some of the largest investment banks along with the attentive, detailed service you expect from a boutique advisory firm. Torreya Partners has offices located in New York, Philadelphia and San Francisco.
SUPPORTERS

Berlin Partner for Business and Technology
www.berlin-partner.de

Business and technology support for companies, investors and scientific institutions in Berlin – this is the Berlin Partner für Wirtschaft und Technologie GmbH mission. With customized services and an excellent science and research network, our many experts provide an outstanding range of programs to help companies launch, innovate, expand and secure their economic future in Berlin.

BIO Deutschland
www.biodeutschland.org

BIO Deutschland is Germany’s biotechnology sector representative at the BDI, the voice of the German Industry, and at the European association, EuropaBio, in Brussels. BIO Deutschland also works closely with other biotech organisations in Europe and the USA in order to lobby for the interests of the sector in an internationally coordinated way. The association is also very active in a broad range of events with the aim of providing biotechnology with a platform for discussion and interaction.

BioPartner
www.biopartner.co.uk

BioPartner is an independent, government-accredited trade organisation, promoting international partnering for trade, investment and collaborations with UK Life Science companies. BioPartner’s delegations promote the UK presence at major international biopharma conferences, and companies are assisted with access to government grants and heavily discounted entry fees. Through the BioPartner Programme, members receive extra benefits and support to effectively trade overseas.

Biotechgate
www.biotechgate.com

Biotechgate is a global, comprehensive, life science database covering the Bio-tech, Pharma and Medtech industries. There are currently over 36,000 company profiles on the Biotechgate database. Biotechgate is commonly used to find product pipelines, collaboration partners, in/out-licensing opportunities and information about technology platforms, management details, new business leads and financing rounds. In addition, our licensing deals database supports companies in negotiating their licensing agreements.
Citigate Dewe Rogerson

www.citigatedr.co.uk

Citigate Dewe Rogerson is one of the world’s leading strategic communications consultancies. Our Life Sciences team has established a reputation for excellence spanning financial, corporate and scientific communications; this has enabled us to become trusted advisors and to build a broad portfolio including some of the most innovative and exciting international life sciences companies. Our clients are at all stages of development, from start-up to multinationals, and our activities are focused on delivering campaigns that support corporate objectives. As a result, we have been involved in major corporate transactions and events in the life sciences sector over the past decade such as IPOs, other public and private fundraisings, and M&As.

Recent IPO transactions: ABIVAX (Euronext Paris - €60m), OSE Pharma (Euronext Paris - €21m), Nordic Nanovector (Oslo – NOK575m), Midatech Pharma (London AIM - £32m), Abzena (London AIM - £20m), arGEN-X (Brussels - €42m), Pixium Vision (Euronext Paris - €39.5m), Crossject (Euronext Paris - €17m). Other recent financings: Abingworth (£225m ABV VI), Rigontec (€14.25m Series A), Calcivis (£4.5m fundraising), ViraTherapeutics ($3.6m - Series A). Recent M&A: Heptares (up to $400m acquisition by Sosei), Prosonix (up to £100m acquisition by Circassia), bioquell (Sale of subsidiary for £44.5m).

Edison Group

www.edisongroup.com

Edison is an international advisory firm with around 450 corporate clients and 110 people working from offices in London, New York, Frankfurt, Sydney and Wellington. The team consists of 80 analysts, investment and logistics professionals with experience in capital markets, investor roadshows and communications. Healthcare is Edison’s largest sector, with 16 analysts covering over 100 biotech and med-tech stocks across the UK, continental Europe, North America and Asia-Pacific.

FreeMind

www.freemindconsultants.com

FreeMind is a consulting group whose goal is to assist in maximizing potential to receive funding from non-dilutive sources. Established in 1999, FreeMind is the largest consulting group of its kind working with academics and Industry alike. FreeMind’s proven long-term strategic approach has garnered its clients over 1.5 billion dollars to date.

Our expertise in applying for grants and contracts extends throughout every government mechanism open to funding the life sciences including all NIH institutes, DoD, NSF, FDA, CDC, BARDA, etc., as well as private foundations.

FreeMind’s knowledgeable and experienced team of Client Strategists and Project Managers are dedicated to guiding non-dilutive funding efforts from identification of the most suitable opportunity through to submission and subsequent award. Our team of experts will assist in making non-dilutive funding a key tool in a long-term financial strategy.
**Instinctif Partners**

www.lifesciences.instinctif.com

Instinctif Partners is an international business communications consultancy. With a track record of delivering truly creative programmes, the Life Sciences practice focuses on enhancing the value proposition for companies seeking investment, partnerships or customers. Our core skill is working with clients to communicate the value of their science and innovation to key stakeholders through the most relevant channels: crafting communications solutions that showcase each company, product or technology. Specifically, we are unique in offering specialist expertise seamlessly across corporate, financial, healthcare and marketing communications with outreach programmes to media, industry, professional, public, financial and investment communities. Our service offering covers all communications disciplines including strategic counsel, PR, IR, media relations, public affairs, crisis communications, internal communications, marketing, advertising, copywriting, design, research and event management. Our globally integrated and dedicated life sciences team serves clients around the world from our headquarters in London, and bases across Europe, AsiaPac and the USA.

**Labiotech.eu**

labiotech.eu/

Labiotech.eu is the leading digital media covering the European Biotech industry. Over 150,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. Hope you’ll enjoy reading our stories!

**Platform Life Sciences**

www.goingpublic.de/lifesciences

The Life Sciences-Series - Launched in 2014 four issues of the Life Sciences-Series appear annually. Based on the three pillars – technology, financing, investment – the issues combine current topics of life sciences with knowledge and networking from corporate financing and capital market. The mission: Building a cross medial bridge between the life sciences and the financial industry by the help of the quarterly Life Sciences issues, the monthly digital newsletter LifeSciencesUpdate.

**SECA**

www.seca.ch

The Swiss Private Equity & Corporate Finance Association (SECA) is the representative body for Switzerland’s private equity, venture capital and corporate finance industries. SECA has the objective to promote private equity and corporate finance activities in Switzerland.

Members of the SECA include equity investment companies, banks, corporate finance advisors, auditing companies, management consultants, lawyers and private investors.
Swiss Biotech Association

www.swissbiotech.org

The Swiss Biotech Association represents the interests of the biotech sector, supports the entrepreneurship of biotech companies, and generates value for them through the following activities:

- Development of optimal framework conditions for the biotech sector:
- Networking of stakeholders at national and international level:
- Dissemination of accomplishments in biotechnology:
- Collaboration with strategic partners

Tiberend Strategic Advisors, Inc.

www.tiberendstrategicadvisors.com

Tiberend Strategic Advisors, Inc. is a corporate communications firm providing media strategy and execution for life science companies – biotech (therapeutics), medical devices and diagnostics. We work with both public and private emerging growth companies:
1. To enhance valuation
2. To build visibility for partnerships and strategic alliances
SACHS ASSOCIATES
www.sachsforum.com

Sachs Associates is a long established international conference company with offices in Switzerland and the UK. It runs a limited number of high profile conferences in Europe and the USA which are focused on biopharma, medtech, and digital health. These conferences focus on licensing and investment opportunities and all provide presenting opportunities for companies and excellent meeting facilities for all delegates to network.

Sachs Associates is focused on the practical benefits accruing from conference participation, the exchange of ideas and information, and the facilitating of business transactions.

THE BENEFITS OF CONFERENCE PARTICIPATION WITH SACHS ASSOCIATES MAY BE SUMMARISED AS FOLLOWS:

ONLINE ONE-2-ONE MEETING SYSTEM

In order to offer the best possible provision for networking opportunities and deal making Sachs Associates provides all delegates access to our online One-2-One meeting system, allowing you to set up, accept or decline private One-2-One meetings with other conference attendees. These meetings last for 20 minutes in duration. Individual passwords and logins are provided to allow immediate access and ensure full security.

CUTTING EDGE CONTENT WITH EMINENT SPEAKERS

Sachs Associates is committed to ensuring that its events continue to provide forums with the participation of the most eminent speakers from the public and private sectors. Through its reputation and its long-established local relationships, the company has attracted very senior scientific and business personalities as speakers at its events.

SPONSORSHIP AND MARKETING OPPORTUNITIES FOR FORTHCOMING EVENTS

Sachs Associates has developed an extensive knowledge of the key individuals operating within the global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at the forefront of the industry and provides a powerful tool by which to increase your company position in this market. Sponsorship of any of our events allows you to raise your company’s profile directly with your potential clients. All of our sponsorship packages are tailor-made to each client, allowing your organisation to gain the most out of attending our industry driven events.

THE FOLLOWING SPONSORSHIP AND MARKETING OPPORTUNITIES ARE AVAILABLE AT FUTURE CONFERENCES:

- Conference Sponsor – including workshops and social events
- Exhibition Stands
- Distribution of Promotional Material

If your company is interested in exhibiting or sponsorship opportunities, please call Silvia Kar on +44 203 463 4890 or email Silvia@sachsforum.com.